{"better_query": "What are the latest advances in cleavable linker technologies for antibody-drug conjugates, including stimuli-responsive and traceless linker designs?", "better_answer": {"sections": [{"title": "Introduction to Cleavable Linkers in ADCs", "tldr": "Cleavable linkers are critical components of antibody-drug conjugates (ADCs) that connect antibodies to cytotoxic payloads and release drugs at target sites. These linkers have evolved significantly to improve stability in circulation while enabling efficient drug release in tumor microenvironments. (LLM Memory)", "text": "\nAntibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs. At the core of ADC design are linkers, which serve as the chemical bridges connecting the antibody to the payload. Cleavable linkers are specifically engineered to remain stable in circulation but undergo selective cleavage upon reaching the target tissue, thereby releasing the active drug at the desired site.\n\nThe fundamental purpose of cleavable linkers is to maintain the ADC's integrity during systemic circulation while enabling controlled drug release within or near tumor cells. This selective release mechanism aims to minimize off-target toxicity while maximizing therapeutic efficacy. Cleavable linkers typically respond to specific conditions or triggers found predominantly in the tumor microenvironment or within cancer cells, such as altered pH, presence of certain enzymes, reducing conditions, or external stimuli.\n\nThe evolution of linker technology has been critical in addressing early challenges faced by first-generation ADCs, including premature drug release, limited plasma stability, and poor pharmacokinetic profiles. As understanding of tumor biology and chemical design principles has advanced, increasingly sophisticated linker systems have emerged that can navigate biological barriers and respond with greater specificity to tumor-associated conditions. <Model name=\"Anthropic\" version=\"claude-3-7-sonnet-20250219\">", "citations": [], "table": null}, {"title": "Traditional Cleavable Linker Technologies", "tldr": "Traditional cleavable linker technologies in ADCs rely on three main mechanisms: enzyme-cleavable peptide bonds, pH-sensitive hydrazone linkages, and reduction-sensitive disulfide bonds. These established linker types exploit the unique conditions of tumor cells or the lysosomal compartment to trigger selective drug release while maintaining stability in circulation. (9 sources)", "text": "\nThe development of traditional cleavable linker technologies has been fundamental to the success of many clinically approved ADCs. These linkers are designed to remain stable in the bloodstream while efficiently releasing their payload in specific biological environments. Three primary types of cleavable linkers have dominated the field: protease-sensitive linkers, pH-sensitive linkers, and glutathione-sensitive linkers <Paper corpusId=\"271112887\" paperTitle=\"(Yim et al., 2024)\" isShortName></Paper>.\n\nEnzyme-cleavable linkers, particularly peptide-based designs, have achieved significant clinical success by exploiting the high concentration of specific hydrolytic enzymes in cellular compartments <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>. The most widely used peptide linkers include valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), and valine-alanine (Val-Ala) dipeptide sequences, which are recognized and cleaved by intracellular proteases such as cathepsin B <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>. These linkers demonstrate enhanced systemic stability due to the unsuitable pH conditions and serum protease inhibitors present in circulation, while enabling rapid enzymatic release of the payload once internalized by target cells <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>.\n\nA common component used in these peptide-based linker systems is para-aminobenzyl carbamate (PABC), which functions as a self-immolative spacer to facilitate the release of an unmodified payload following peptide bond cleavage <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>. This self-cleavage capacity is particularly important for maintaining drug potency after release.\n\npH-sensitive linkers, particularly hydrazone-containing structures, exploit the acidic environment of late endosomes and lysosomes (pH 4.5-6.0) to trigger payload release <Paper corpusId=\"271549527\" paperTitle=\"(Perez et al., 2024)\" isShortName></Paper> <Paper corpusId=\"256771727\" paperTitle=\"(Holz et al., 2023)\" isShortName></Paper>. These acid-labile linkers remain stable at physiological pH (7.4) but undergo hydrolysis when exposed to the lower pH of intracellular compartments <Paper corpusId=\"251651157\" paperTitle=\"(Schwach et al., 2022)\" isShortName></Paper>.\n\nThe third major category of traditional cleavable linkers consists of reduction-sensitive disulfide bonds, which take advantage of the high concentration of glutathione and reductive environment within tumor cells <Paper corpusId=\"256771727\" paperTitle=\"(Holz et al., 2023)\" isShortName></Paper>. Disulfide linkers remain intact in the oxidizing extracellular environment but undergo rapid reduction in the cytoplasm where glutathione concentrations are significantly elevated compared to plasma <Paper corpusId=\"255967333\" paperTitle=\"(Conilh et al., 2023)\" isShortName></Paper>.\n\nEach of these traditional linker technologies presents unique advantages and limitations. While chemically labile linkers (such as hydrazones and disulfides) often have limited plasma stability leading to premature drug release, enzyme-cleavable peptide linkers typically offer improved stability in circulation <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>. Additionally, cleavable linkers generally generate membrane-permeable payloads capable of promoting bystander killing, which can be advantageous for treating heterogeneous tumors <Paper corpusId=\"271549527\" paperTitle=\"(Perez et al., 2024)\" isShortName></Paper>.\n\nThe careful selection of linker technology is critical for balancing stability in circulation with efficient drug release at the target site <Paper corpusId=\"249284297\" paperTitle=\"(Eras et al., 2022)\" isShortName></Paper> <Paper corpusId=\"18023696\" paperTitle=\"(Lu et al., 2016)\" isShortName></Paper>. These traditional cleavable linker designs have set the foundation for more recent innovations aimed at enhancing specificity, stability, and overall ADC performance <Paper corpusId=\"272912954\" paperTitle=\"(Moore et al., 2024)\" isShortName></Paper>.", "citations": [{"id": "(Yim et al., 2024)", "paper": {"corpus_id": 271112887, "title": "Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation", "year": 2024, "venue": "ChemMedChem", "authors": [{"name": "Junhyeong Yim", "authorId": "2310805820"}, {"name": "Junyoung Park", "authorId": "2310858106"}, {"name": "Gabin Kim", "authorId": "2310855697"}, {"name": "Hyung Ho Lee", "authorId": "2326804357"}, {"name": "Jin Soo Chung", "authorId": "2326821221"}, {"name": "Ala Jo", "authorId": "120937238"}, {"name": "Minseob Koh", "authorId": "2279946070"}, {"name": "Jongmin Park", "authorId": "2305645972"}], "n_citations": 4}, "snippets": ["For the chemical linker in ADCs, both cleavable and non-cleavable chemical structures have been utilized. Cleavable linkers enable controlled release of the cytotoxic payload intracellularly or within the tumor microenvironment. The cleavable ADC linkers can be categorized into three types: protease-sensitive linkers utilizing protease cleavable peptide sequences like cathepsin B sensitive valine-citrulline (VC) dipeptide, pH-sensitive linkers attached to acid-labile groups such as hydrazone, and glutathione-sensitive linkers containing disulfide bonds. Whereas, non-cleavable linkers, including thioether or maleimidocaproyl (MC) groups, exhibit enhanced plasma stability, and potentially improving the therapeutic index. [44]"], "score": 0.794921875}, {"id": "(Sheyi et al., 2022)", "paper": {"corpus_id": 246783968, "title": "Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate", "year": 2022, "venue": "Pharmaceutics", "authors": [{"name": "Rotimi Sheyi", "authorId": "1412635073"}, {"name": "B. G. de la Torre", "authorId": "4279044"}, {"name": "F. Albericio", "authorId": "3976878"}], "n_citations": 110}, "snippets": ["Chemically labile linkers often have limited plasma stability, thereby leading to premature drug release.In this regard, as an alternative strategy, enzyme-cleavable linkers have achieved clinical success in controlled drug release.Unlike chemically labile linkers, enzyme-cleavable ones take advantage of the high concentration of unique hydrolytic enzymes in cellular compartments to degrade peptides and carbohydrates.\n\nPeptide-based linkers, also known as lysosomal protease-sensitive linkers, such as valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), and valine-alanine (Val-Ala) dipeptide linkers, are the most widely used linkers in ADC design.This strategy utilizes intracellular protease, such as Cathepsin B, which recognizes and cleaves a dipeptide bond, thus leading to the release of the cytotoxic drugs [89].Due to unsuitable pH conditions and serum protease inhibitors, peptide-based linkers show greater systemic stability, with rapid enzymatic release of the payload in the target cell [90].Exploring these types of linkers in ADC development often requires a conjugating spacer molecule due to the bulky nature of payload.The reagent most commonly used for this purpose is para-aminobenzyl carbamate (PABC) (Figure 8), which shows self-cleavage capacity, thereby facilitating the release of the unmodified payload [70]."], "score": 0.845703125}, {"id": "(Perez et al., 2024)", "paper": {"corpus_id": 271549527, "title": "Single-Domain Antibodies as Antibody\u2013Drug Conjugates: From Promise to Practice\u2014A Systematic Review", "year": 2024, "venue": "Cancers", "authors": [{"name": "V\u00edctor Manuel Medina P\u00e9rez", "authorId": "2231602711"}, {"name": "Marta Baselga", "authorId": "2302155081"}, {"name": "A. J. Schuhmacher", "authorId": "38641288"}], "n_citations": 6}, "snippets": ["Linkers must maintain the ADC's stability in the bloodstream to ensure it reaches the cancer cell intact, but they must also be able to be easily cleaved upon internalization (cleavable linkers) to release the payload. Alternatively, non-cleavable linkers should form an innocuous element after releasing the payload, allowing it to still exert its therapeutic effect (Fu et al., 2022)(Dumontet et al., 2023)(Tarantino et al., 2023)(Drago et al., 2021)(Beck et al., 2017)(Matsumura et al., 1986)(Matsumura, 2014)(Joubert et al., 2020)(Riccardi et al., 2023)(Jin et al., 2021). Cleavable linkers are designed to be processed at the tumor site, taking advantage of the unique properties of the tumor microenvironment over healthy tissues or systemic circulation. They can be released from the antibody by changes in pH or by enzymes present in the intercellular and intracellular space. These types of linkers generate a membrane-permeable neutral payload capable of promoting bystander killing [31,[41][42][43][44][45]."], "score": 0.9208984375}, {"id": "(Holz et al., 2023)", "paper": {"corpus_id": 256771727, "title": "A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future", "year": 2023, "venue": "Pharmaceutics", "authors": [{"name": "E. Holz", "authorId": "2082884205"}, {"name": "Martine Darwish", "authorId": "49955694"}, {"name": "Devin B. Tesar", "authorId": "5899408"}, {"name": "Whitney Shatz-Binder", "authorId": "2150802806"}], "n_citations": 25}, "snippets": ["Advancements in linker design are key contributors to the clinical success of ADCs. Linkers must be able to keep the cytotoxic payload stable in plasma, but then must also facilitate rapid and efficient release of the active drug in tumor cells. Both cleavable and noncleavable linkers have been successfully employed in approved ADCs ( Table 1). Payloads that require release of the unmodified free drug upon internalization in the tumor cell to maintain drug potency require a cleavable linker. Cleavable linker technologies most widely used are reducible disulfides, acid labile-hydrazones, and protease cleavable dipeptides (Bargh et al., 2019). Upon internalization by receptor-mediated endocytosis, ADCs enter the endosomal to lysosomal pathway, where they are exposed to changing cellular conditions. The acidic environment of the late endosome promotes drug release from pH-sensitive hydrazone linkers, while disulfide linkages are cleaved by reduction due to the high concentration of glutathione present in tumor cells [10]."], "score": 0.708984375}, {"id": "(Schwach et al., 2022)", "paper": {"corpus_id": 251651157, "title": "More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.", "year": 2022, "venue": "Frontiers in Bioscience", "authors": [{"name": "Jonathan Schwach", "authorId": "2027067779"}, {"name": "Mustafa Abdellatif", "authorId": "2181932117"}, {"name": "A. Stengl", "authorId": "5060159"}], "n_citations": 14}, "snippets": ["Not only the conjugation method but also the linker itself is an integral and customizable element of ADCs. Apart from physically linking drug and antibody it also has the potential to contribute to characteristics like linkage stability, drug release and aggregation behavior (Lyon et al., 2015). Currently approved ADCs utilize either non-cleavable, chemically cleavable or cathepsin-cleavable linkers for intracellular liberation of cytotoxins. Non-cleavable linkers liberate the attached drug upon proteasomal degradation of the internalized antibody [119]. In this case the drug remains attached to the conjugated amino acid which can affect its bio-distribution and potency (Lu et al., 2016). Cleavable linkers on the contrary allow triggered release. Currently approved ADCs are designed to exploit the distinct environment in lysosomes to trigger drug release. For example, pH sensitive or thiol-containing reduction-labile linker elements, found in gemtuzumab ozogamicin (Mylotarg [121]) and inotuzmab ozogamicin (Besponsa [122]), exploit the acidic and reductive milieu in lysosomes."], "score": 0.87353515625}, {"id": "(Conilh et al., 2023)", "paper": {"corpus_id": 255967333, "title": "Payload diversification: a key step in the development of antibody\u2013drug conjugates", "year": 2023, "venue": "Journal of Hematology & Oncology", "authors": [{"name": "L. Conilh", "authorId": "1768154554"}, {"name": "L. Sad\u00edlkov\u00e1", "authorId": "3561670"}, {"name": "W. Viricel", "authorId": "11233897"}, {"name": "C. Dumontet", "authorId": "32058344"}], "n_citations": 103}, "snippets": ["The linker plays a major role in ADC design since it strongly impacts on the safety, potency and activity of the ADC. Most importantly, the linker is expected to remain stable in circulation to avoid premature detachment of the drug while allowing its release within the targeted cell. Two categories of linkers have been developed and can be distinguished based on their cleavability. Cleavable linkers are either sensitive to pH for hydrazone linkers, to glutathione or disulfide isomerase for disulfide linkers and to proteases such as cathepsin B for dipeptide bonds. Non-cleavable linkers rely on lysosomal degradation of the antibody moiety, thereby conserving at least one amino acid, most commonly lysine or cysteine, attached to the payload-linker complex", "recent interest in linker design improvement has led to the development of hydrophilic linkers to balance payload hydrophobicity (Buecheler et al., 2018)(Ratanji et al., 2013)(Lyon et al., 2015)(Hamblett et al., 2004). Sulfonate, polyethylene glycol (PEG), polysarcosine (PSAR) or more recently DNA-based linkers have significantly improved ADC stability and pharmacokinetics, leading to less toxic and more active ADCs [30][31][32][33][34][35][36][37]."], "score": 0.88720703125}, {"id": "(Eras et al., 2022)", "paper": {"corpus_id": 249284297, "title": "Chemical Conjugation in Drug Delivery Systems", "year": 2022, "venue": "Frontiers in Chemistry", "authors": [{"name": "Alexis Eras", "authorId": "2167595634"}, {"name": "D. Castillo", "authorId": "2167599176"}, {"name": "M. Su\u00e1rez", "authorId": "144033469"}, {"name": "N. Vispo", "authorId": "10102959"}, {"name": "F. Albericio", "authorId": "3976878"}, {"name": "H. Rodr\u00edguez", "authorId": "13987983"}], "n_citations": 23}, "snippets": ["As mentioned before, the drugs could be conjugated directly to the antibody. However, the linkers have helped prepare ADCs to facilitate bioconjugation reactions. Among the advantages of using a linker are preventing premature drug release, improving the liberation of the active drug at the target, and facilitating stability in the production process. The most important aspect of the linker is its physicochemical properties, which allows defining two main different kinds of linker: \n\nCleavable linker: It is characteristic of breaking one of its chemical bonds that binds the two molecular entities. This kind of linker has been successful in elaborating ADCs due to its stability in the synthesis process and the blood circulation of the conjugate for a long time. It allows the releasing of the drug under some conditions at the surrounding of the target cell or tissue-like overexpression of enzyme or acidic environment (Lu et al., 2016)Ramos Tomillero, 2016;(Kostova et al., 2021)."], "score": 0.71484375}, {"id": "(Lu et al., 2016)", "paper": {"corpus_id": 18023696, "title": "Linkers Having a Crucial Role in Antibody\u2013Drug Conjugates", "year": 2016, "venue": "International Journal of Molecular Sciences", "authors": [{"name": "Jun Lu", "authorId": "49301713"}, {"name": "Feng Jiang", "authorId": "2069981623"}, {"name": "Aiping Lu", "authorId": "2086739714"}, {"name": "Ge Zhang", "authorId": "144336463"}], "n_citations": 223}, "snippets": ["Antibody\u2013drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, enhancing the therapeutic parameter of the cytotoxic drug and reducing the possibility of systemic cytotoxicity. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs\u2019 stability during the preparation and storage stages of the ADCs and during the systemic circulation period. The design of linkers for ADCs is a challenge in terms of extracellular stability and intracellular release, and intracellular circumstances, such as the acid environment, the reducing environment and cathepsin, are considered as the catalysts to activate the triggers for initiating the cleavage of ADCs. This review discusses the linkers used in the clinical and marketing stages for ADCs and details the fracture modes of the linkers for the further development of ADCs."], "score": 0.0}, {"id": "(Moore et al., 2024)", "paper": {"corpus_id": 272912954, "title": "Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer", "year": 2024, "venue": "Xenobiotica; the fate of foreign compounds in biological systems", "authors": [{"name": "Eric J Moore", "authorId": "2323019381"}, {"name": "Megan Rice", "authorId": "2323018449"}, {"name": "Gourgopal Roy", "authorId": "2323023067"}, {"name": "Wenting Zhang", "authorId": "2323032564"}, {"name": "M. Marelli", "authorId": "2323019209"}], "n_citations": 1}, "snippets": ["To expand the therapeutic window, much research has been devoted to the development of cleavable and non-cleavable linkers that improve the stability, hydrophobicity, and specific release of the cytotoxic payloads. Ideally, linkers are stable in circulation and release payload in cancer cells. To achieve this dual functionality, linkers with diverse release triggers have been developed including pH sensitive linkers, enzyme cleavable linkers (i.e. specifically cleaved by cathepsins, glycosidases, or sulfatases), and photo-sensitive linkers."], "score": 0.84912109375}], "table": null}, {"title": "Recent Advances in Stimuli-Responsive Linker Designs", "tldr": "Recent innovations in ADC linker technology have expanded beyond traditional mechanisms to include stimuli-responsive designs that offer greater precision in payload release. These advanced linkers respond to specific triggers such as light, enzymes, pH changes, and bioorthogonal reactions, enabling more targeted delivery with reduced off-target toxicity. (13 sources)", "text": "\nThe evolution of antibody-drug conjugate (ADC) technology has seen significant advancements in linker designs that respond to specific stimuli, providing enhanced control over payload release. These next-generation stimuli-responsive linkers aim to address the limitations of traditional linker technologies by offering improved stability in circulation while enabling more precise release mechanisms at target sites <Paper corpusId=\"263654364\" paperTitle=\"(Zhang et al., 2023)\" isShortName></Paper>.\n\nPhotoactivatable linkers have emerged as a promising non-invasive technology that allows for controlled release of cytotoxic payloads with high spatiotemporal precision. These light-sensitive linkers remain stable until triggered by specific wavelengths of light, minimizing off-target toxicity in the absence of irradiation and demonstrating increased stability compared to conventional internally-triggered linker strategies <Paper corpusId=\"249073474\" paperTitle=\"(Johan et al., 2022)\" isShortName></Paper>. The development of UV-triggered systems (using coumarin, ortho-nitrobenzyl groups, or thioacetal ortho-nitrobenzaldehyde) and IR-triggered systems (employing cyanine and BODIPY) has expanded the toolbox for photo-controlled drug release <Paper corpusId=\"271530455\" paperTitle=\"(He et al., 2024)\" isShortName></Paper> <Paper corpusId=\"249073474\" paperTitle=\"(Johan et al., 2022)\" isShortName></Paper>.\n\npH-sensitive linker technologies have also advanced beyond traditional hydrazone structures to create more stable and selective systems. These newer designs exploit the acidic tumor microenvironment or the lower pH of endosomal/lysosomal compartments to trigger payload release <Paper corpusId=\"267826318\" paperTitle=\"(Sbihi et al., 2024)\" isShortName></Paper> <Paper corpusId=\"269134251\" paperTitle=\"(Niazi et al., 2024)\" isShortName></Paper>. Examples include improved hydrazone linkers that remain intact at physiological pH (7.4) but undergo controlled hydrolysis in acidic environments (pH 4.5-6.0), as well as acetal-based linkers that demonstrate similar pH-dependent behavior <Paper corpusId=\"269134251\" paperTitle=\"(Niazi et al., 2024)\" isShortName></Paper>.\n\nEnzyme-responsive linkers have expanded beyond cathepsin B-cleavable designs to include those responsive to additional lysosomal proteases such as sulfatases and legumain <Paper corpusId=\"267191025\" paperTitle=\"(Metrangolo et al., 2024)\" isShortName></Paper> <Paper corpusId=\"258773396\" paperTitle=\"(Grier et al., 2023)\" isShortName></Paper>. For instance, sulfatase-sensitive linkers have been developed that show efficient enzyme-mediated release of alcohol-containing payloads while maintaining high stability in plasma <Paper corpusId=\"267191025\" paperTitle=\"(Metrangolo et al., 2024)\" isShortName></Paper>.\n\nA particularly innovative development is the emergence of bioorthogonal cleavable linkers, which use chemical reactions that can occur in biological systems without interfering with native biochemical processes <Paper corpusId=\"267191025\" paperTitle=\"(Metrangolo et al., 2024)\" isShortName></Paper> <Paper corpusId=\"271530455\" paperTitle=\"(He et al., 2024)\" isShortName></Paper>. These include metal-mediated cleavable linkers based on palladium, ruthenium, copper, and platinum that allow for well-controlled payload release through bioorthogonal bond cleavage reactions <Paper corpusId=\"270803831\" paperTitle=\"(Chis et al., 2024)\" isShortName></Paper>. Such approaches hold promise for overcoming the intracellular drug release limitations seen in traditional ADCs <Paper corpusId=\"263654364\" paperTitle=\"(Zhang et al., 2023)\" isShortName></Paper>.\n\nSelf-immolative linkers have also been refined to respond to specific stimuli such as pH changes, redox conditions, or light <Paper corpusId=\"250453738\" paperTitle=\"(Salerno et al., 2022)\" isShortName></Paper>. These linkers undergo a cascade of chemical reactions when triggered, resulting in complete breakdown of the linker and release of an unmodified therapeutic agent <Paper corpusId=\"273979041\" paperTitle=\"(Parashar et al., 2024)\" isShortName></Paper>.\n\nThe advancement in site-specific conjugation technologies has complemented these stimuli-responsive linker developments, allowing for the creation of homogeneous ADC constructs with superior therapeutic indices <Paper corpusId=\"267191025\" paperTitle=\"(Metrangolo et al., 2024)\" isShortName></Paper> <Paper corpusId=\"246783968\" paperTitle=\"(Sheyi et al., 2022)\" isShortName></Paper>. These precision techniques ensure that linkers and payloads are attached at defined positions on the antibody, further enhancing ADC stability and performance.\n\nDespite these innovations, researchers continue to face challenges in optimizing linker parameters, including conjugation chemistry, linker length, and steric hindrance, all of which significantly impact ADC stability, efficacy, and toxicity profiles <Paper corpusId=\"263654364\" paperTitle=\"(Zhang et al., 2023)\" isShortName></Paper> <Paper corpusId=\"266461864\" paperTitle=\"(Li et al., 2023)\" isShortName></Paper>. The ideal balance between stability in circulation and efficient payload release at target sites remains a central focus of ongoing research <Paper corpusId=\"263654364\" paperTitle=\"(Zhang et al., 2023)\" isShortName></Paper> <Paper corpusId=\"197400937\" paperTitle=\"(Lin et al., 2019)\" isShortName></Paper>.", "citations": [{"id": "(Zhang et al., 2023)", "paper": {"corpus_id": 263654364, "title": "Designing Bioorthogonal Reactions for Biomedical Applications", "year": 2023, "venue": "Research", "authors": [{"name": "Qingfei Zhang", "authorId": "1492024058"}, {"name": "Gaizhen Kuang", "authorId": "14186308"}, {"name": "Li Wang", "authorId": "2254447152"}, {"name": "Ping Duan", "authorId": "2253554410"}, {"name": "Weijian Sun", "authorId": "2253942415"}, {"name": "Fangfu Ye", "authorId": "2253596323"}], "n_citations": 6}, "snippets": ["The development of ADCs has advanced substantially in the past decade, driven by improvements in payloads, linkers, and coupling techniques (Markham, 2020)(Su et al., 2021). Notably, linker design plays a pivotal role in governing ADC stability in systemic circulation and payload delivery efficiency in tumors, thereby influencing pharmacokinetics (PK), efficacy, and toxicity profiles (Su et al., 2021)(Lin et al., 2019). Key linker parameters, including coupling chemistry, length, and steric hindrance, profoundly impact ADC performance (Bargh et al., 2019). The ideal linker should maintain stability in circulation while releasing cytotoxic payloads within tumors (Srinivasarao et al., 2017). However, existing linkers often release payloads unpredictably, leading to off-target toxicity. Thus, in ADC design, precise adjustment of these linker parameters is imperative to strike a balance between stability and payload release efficiency, ensuring the desired therapeutic effect. Recent years have witnessed substantial progress in optimizing ADC structures and diversifying their mechanisms (Ducry, 2013). Novel cleavable linkers, especially bioorthogonal ones, hold promise for overcoming intracellular drug release limitations seen in traditional ADCs [156]."], "score": 0.9150390625}, {"id": "(Johan et al., 2022)", "paper": {"corpus_id": 249073474, "title": "Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody\u2013Drug Conjugates for Cancer Therapy", "year": 2022, "venue": "Pharmaceuticals", "authors": [{"name": "Audrey Nathania Johan", "authorId": "2166371328"}, {"name": "Yi Li", "authorId": "2153683439"}], "n_citations": 3}, "snippets": ["In recent years, photocleavable linkers have been developed as a non-invasive technology, allowing the controlled release of the active substance with high spatiotemporal precision. Along with the utilization of carriers that take advantage of active targeting strategies such as monoclonal antibodies, this strategy of drug delivery becomes a powerful tool in clinical cancer therapy. As seen from the research on the photoremovable linkers so far, the drug conjugates, especially ADC, have shown minimal off-target toxicity without irradiation and increased stability compared to other conventional ADCs utilizing an internal trigger linker strategy. In addition, the linker modulates ADC stability in the systemic circulation and payload release efficiency, in the meantime affecting ADC pharmacokinetic (PK), efficacy and toxicity profiles. Conjugation chemistry, linker length, and linker steric hindrance are among the key linker parameters to be considered in order to achieve a balance between stability and efficacy in the integrated strategies."], "score": 0.9208984375}, {"id": "(He et al., 2024)", "paper": {"corpus_id": 271530455, "title": "Antibody\u2013drug conjugates in cancer therapy: mechanisms and clinical studies", "year": 2024, "venue": "MedComm", "authors": [{"name": "Jun He", "authorId": "2313693400"}, {"name": "Xianghua Zeng", "authorId": "2311129375"}, {"name": "Chunmei Wang", "authorId": "2313593920"}, {"name": "Enwen Wang", "authorId": "2308628280"}, {"name": "Yongsheng Li", "authorId": "2310603528"}], "n_citations": 7}, "snippets": ["In recent decades, significant progress has been made in optimizing the structure and expanding the mechanisms of ADCs. These novel cleavable linkers have shown increased selectivity for targeting tumors. Among them, cathepsin, glutathione, and acid-cleavable linkers have been extensively researched and incorporated into approved ADCs. Notably, phosphatase-responsive and bioorthogonal cleavable linkers have the potential to overcome intracellular drug release limitations seen in traditional ADCs. Early data on these new linkers are promising and are expected to significantly advance the development of ADC drugs in the future."], "score": 0.92822265625}, {"id": "(Sbihi et al., 2024)", "paper": {"corpus_id": 267826318, "title": "Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma", "year": 2024, "venue": "Cancers", "authors": [{"name": "Ali Al Sbihi", "authorId": "2285521896"}, {"name": "Maryam Alasfour", "authorId": "2285520155"}, {"name": "G. Pongas", "authorId": "5631721"}], "n_citations": 7}, "snippets": ["As for recent advances in linkers, efforts are focused on manufacturing linkers that are stable to avoid off-target payload release but also easily cleavable to deliver at the target site effectively. This leads to manufacturing linkers with pH and microenvironment-dependent cleavage, allowing ADCs to release the payload inside the cell (Schwach et al., 2022)."], "score": 0.8291015625}, {"id": "(Niazi et al., 2024)", "paper": {"corpus_id": 269134251, "title": "Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody\u2013Transferrin Conjugates", "year": 2024, "venue": "Biomedicines", "authors": [{"name": "Sarfaraz K. Niazi", "authorId": "152158686"}, {"name": "Matthias Magoola", "authorId": "2266944635"}], "n_citations": 2}, "snippets": ["Several considerations must be considered when selecting a linker to bind an antibody to transferrin to facilitate entry into the brain", "Various cleavable linkers, such as protease-sensitive or pH-sensitive linkers, can be considered (Pardridge, 2015)(Salvati et al., 2013)", "the linker should maintain stability in the bloodstream to prevent premature release of the antibodytransferrin conjugate. Stability can be influenced by factors such as serum proteases and pH (Pardridge, 2007)", "the linker should be designed to be cleavable within the unique microenvironment of the BBB, which may have different enzymatic activities or pH compared to other tissues [76].\n\nThe pH-sensitive linkers play a crucial role in drug delivery systems, as they are designed to remain stable at physiological pH but become cleavable under acidic conditions typically found in endosomes or lysosomes. One example is hydrazone linkers, which form via the reaction between a hydrazide and a carbonyl group under acidic conditions. They exhibit stability at neutral pH but undergo hydrolysis in acidic environments, facilitating linker cleavage. This mechanism has been utilized in various drug delivery systems, including liposomes and polymer conjugates [78]. Another commonly used pH-sensitive linker is the acetal linker, which remains stable at neutral pH but undergoes acid-catalyzed hydrolysis to release the payload under acidic conditions."], "score": 0.87841796875}, {"id": "(Metrangolo et al., 2024)", "paper": {"corpus_id": 267191025, "title": "Antibody\u2013Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs", "year": 2024, "venue": "Cancers", "authors": [{"name": "Virginia Metrangolo", "authorId": "2136179643"}, {"name": "L. Engelholm", "authorId": "48038664"}], "n_citations": 28}, "snippets": ["Other recently emerged cleavable linker classes with higher plasma stability include lysosomal protease-cleavable linkers such as sulfatase-and legumain-cleavable linkers [53](Grier et al., 2023), while more innovative, albeit still exploratory, linker technologies include photo-sensitive and biorthogonal cleavable linkers, which widen up the opportunity for nonendocytic ADCs (Sheyi et al., 2022)(Su et al., 2021). Paralleling the efforts in improving ADCs pharmacology is the expanding development of site-specific linkers and conjugation technologies, which allow for homogeneous constructs with superior therapeutic indices (Sheyi et al., 2022)(Su et al., 2021), as described in the following section."], "score": 0.970703125}, {"id": "(Grier et al., 2023)", "paper": {"corpus_id": 258773396, "title": "Targeted delivery of alcohol-containing payloads with antibody-drug conjugates.", "year": 2023, "venue": "Chemical Communications", "authors": [{"name": "Katja E Grier", "authorId": "50856771"}, {"name": "A. Hansen", "authorId": "36872315"}, {"name": "Christina Haxvig", "authorId": "2217786255"}, {"name": "Xin Li", "authorId": "2153897849"}, {"name": "Oliver Krigslund", "authorId": "1705404617"}, {"name": "Niels Behrendt", "authorId": "2293091599"}, {"name": "L. Engelholm", "authorId": "48038664"}, {"name": "Fabio Rossi", "authorId": "2217618070"}, {"name": "B. Sousa", "authorId": "16192094"}, {"name": "Grant Harradence", "authorId": "2217782375"}, {"name": "N. Camper", "authorId": "48991974"}, {"name": "Katrine M Qvortrup", "authorId": "40591303"}], "n_citations": 1}, "snippets": ["We herein describe the cell-specific release of alcohol-containing payloads via a sulfatase-sensitive linker in antibody-drug conjugates (ADCs). The linker shows efficient sulfatase-mediated release and high stability in human and mouse plasma. In vitro evaluation demonstrates potent antigen dependent toxicity towards breast cancer cell lines."], "score": 0.0}, {"id": "(Chis et al., 2024)", "paper": {"corpus_id": 270803831, "title": "Antibody\u2013Drug Conjugates\u2014Evolution and Perspectives", "year": 2024, "venue": "International Journal of Molecular Sciences", "authors": [{"name": "A. A. Chi\u0219", "authorId": "1931691698"}, {"name": "C. Dobrea", "authorId": "113090506"}, {"name": "A. Arseniu", "authorId": "1932174913"}, {"name": "Adina Frum", "authorId": "90626113"}, {"name": "L. Rus", "authorId": "27468075"}, {"name": "Gabriela Cormo\u0219", "authorId": "11187766"}, {"name": "Cecilia Georgescu", "authorId": "2276865399"}, {"name": "C. Morgovan", "authorId": "27000607"}, {"name": "Anca Butuca", "authorId": "1436195146"}, {"name": "F. Gligor", "authorId": "66240760"}, {"name": "A. L. Vonica-\u021aincu", "authorId": "1932172800"}], "n_citations": 8}, "snippets": ["Studies have been carried out on the approach of new metal-mediated cleavable linkers with singlecaged fragments that are designed for well-controlled payload release by the bioorthogonal bond cleavage reaction and toxicity diminution by substoichiometric amounts of metals that can reach the desired effectiveness [167,168]. Metal-mediated linkers are based on palladium, ruthenium, copper, and platinum [169]."], "score": 0.8232421875}, {"id": "(Salerno et al., 2022)", "paper": {"corpus_id": 250453738, "title": "Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One", "year": 2022, "venue": "Journal of Medicinal Chemistry", "authors": [{"name": "A. Salerno", "authorId": "114225997"}, {"name": "Francesca Seghetti", "authorId": "51129698"}, {"name": "Jessica Caciolla", "authorId": "2027060085"}, {"name": "Elisa Uliassi", "authorId": "4769326"}, {"name": "Eleonora Testi", "authorId": "2175804080"}, {"name": "Melissa Guardigni", "authorId": "22809166"}, {"name": "M. Roberti", "authorId": "145619100"}, {"name": "A. Milelli", "authorId": "145926264"}, {"name": "M. Bolognesi", "authorId": "34856164"}], "n_citations": 28}, "snippets": ["In most cases, release occurs following linker cleavage by intracellular thiols (Lee et al., 2013) or by using selfimmolative linkers responsive to specific stimuli, such as pH, redox system, and light. (Li et al., 2019)(Gonzaga et al., 2020)"], "score": 0.7177734375}, {"id": "(Parashar et al., 2024)", "paper": {"corpus_id": 273979041, "title": "Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy", "year": 2024, "venue": "Discover Oncology", "authors": [{"name": "Ashish Kumar Parashar", "authorId": "2256891951"}, {"name": "G. Saraogi", "authorId": "11995113"}, {"name": "Pushpendra Kumar Jain", "authorId": "2330371554"}, {"name": "B. Kurmi", "authorId": "12604174"}, {"name": "Vivek Shrivastava", "authorId": "2330302884"}, {"name": "Vandana Arora", "authorId": "2259667676"}], "n_citations": 11}, "snippets": ["Cleavable linkers are designed to be stable in the bloodstream to prevent premature drug release. Once they reach the target site, such as a tumor, they can be cleaved through various mechanisms. For instance, linkers can be pH-sensitive, cleaving in the acidic environment of tumors or inflamed tissue. Alternatively, they can be enzyme-sensitive, breaking down in the presence of certain enzymes overexpressed in disease states [70,71].\n\nSelf-Immolative linker undergoes a cascade of chemical reactions triggered by a stimulus (like an enzyme or pH change), resulting in the complete breakdown of the linker and release of the drug [72]. This design allows for a more precise and complete release of the therapeutic agent."], "score": 0.90771484375}, {"id": "(Sheyi et al., 2022)", "paper": {"corpus_id": 246783968, "title": "Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate", "year": 2022, "venue": "Pharmaceutics", "authors": [{"name": "Rotimi Sheyi", "authorId": "1412635073"}, {"name": "B. G. de la Torre", "authorId": "4279044"}, {"name": "F. Albericio", "authorId": "3976878"}], "n_citations": 110}, "snippets": ["Chemically labile linkers often have limited plasma stability, thereby leading to premature drug release.In this regard, as an alternative strategy, enzyme-cleavable linkers have achieved clinical success in controlled drug release.Unlike chemically labile linkers, enzyme-cleavable ones take advantage of the high concentration of unique hydrolytic enzymes in cellular compartments to degrade peptides and carbohydrates.\n\nPeptide-based linkers, also known as lysosomal protease-sensitive linkers, such as valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), and valine-alanine (Val-Ala) dipeptide linkers, are the most widely used linkers in ADC design.This strategy utilizes intracellular protease, such as Cathepsin B, which recognizes and cleaves a dipeptide bond, thus leading to the release of the cytotoxic drugs [89].Due to unsuitable pH conditions and serum protease inhibitors, peptide-based linkers show greater systemic stability, with rapid enzymatic release of the payload in the target cell [90].Exploring these types of linkers in ADC development often requires a conjugating spacer molecule due to the bulky nature of payload.The reagent most commonly used for this purpose is para-aminobenzyl carbamate (PABC) (Figure 8), which shows self-cleavage capacity, thereby facilitating the release of the unmodified payload [70]."], "score": 0.845703125}, {"id": "(Li et al., 2023)", "paper": {"corpus_id": 266461864, "title": "Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives", "year": 2023, "venue": "Frontiers in Oncology", "authors": [{"name": "Keqiang Li", "authorId": "2237041393"}, {"name": "Guoqing Xie", "authorId": "2275644156"}, {"name": "Xiyue Deng", "authorId": "2275826159"}, {"name": "Yu Zhang", "authorId": "2276130644"}, {"name": "Zhankui Jia", "authorId": "2072783284"}, {"name": "Zhenlin Huang", "authorId": "2275997017"}], "n_citations": 4}, "snippets": ["Traditional cleavable linkers have been used, which are designed to release payloads intracellularly in response to pH changes or the action of specific enzymes. In contrast, non-cleavable linkers necessitate complete antibody degradation for payload release. Current research is focused on developing novel linkers that offer optimal stability, solubility, and release profiles, as well as site-specific conjugation methods (24,25)."], "score": 0.77099609375}, {"id": "(Lin et al., 2019)", "paper": {"corpus_id": 197400937, "title": "Bioorthogonal Prodrug\u2013Antibody Conjugates for On-Target and On-Demand Chemotherapy", "year": 2019, "venue": "CCS Chemistry", "authors": [{"name": "F. Lin", "authorId": "2113697584"}, {"name": "Long Chen", "authorId": "2118172224"}, {"name": "Heng Zhang", "authorId": "71777814"}, {"name": "W. S. C. Ngai", "authorId": "3365794"}, {"name": "Xiangmei Zeng", "authorId": "2111552023"}, {"name": "Jian Lin", "authorId": "144491764"}, {"name": "Peng R. Chen", "authorId": "2158171940"}], "n_citations": 22}, "snippets": ["Current antibody\u2013drug conjugates (ADCs) suffer from low tissue penetration and significant side effects, largely due to the permanent linkage and/or premature release of cytotoxic payloads. Herein, we developed a prodrug\u2013antibody conjugate (ProADC) strategy by conjugating a bioorthogonal-activatable prodrug with an antibody that allowed on-target release and on-demand activation of cytotoxic drugs at a tumor site. The bioorthogonal-caged prodrug exhibited an enhanced permeability into and on-demand activation within cancer cells, while the pH-sensitive ADC linker allowed on-target release of the anticancer agent. Together, the ProADCs showed enhanced tumor penetration and alleviated side effects for use as an on-target and on-demand chemotherapy agents."], "score": 0.0}], "table": null}, {"title": "Self-Immolative Linker Chemistry Advancements", "tldr": "Self-immolative linker chemistry has evolved significantly from traditional PABC spacers to more sophisticated designs that enable efficient and traceless payload release. These advances include disulfide bridge technologies, specialized peptide sequences, thiol-responsive systems, and zwitterionic linkers that improve ADC stability while maintaining effective intracellular drug delivery. (8 sources)", "text": "\nSelf-immolative linkers play a crucial role in ADC technology by undergoing a cascade of chemical reactions upon initial triggering, resulting in complete linker breakdown and release of unmodified therapeutic agents <Paper corpusId=\"273979041\" paperTitle=\"(Parashar et al., 2024)\" isShortName></Paper> <Paper corpusId=\"18023696\" paperTitle=\"(Lu et al., 2016)\" isShortName></Paper> <Paper corpusId=\"2862021\" paperTitle=\"(Dosio et al., 2011)\" isShortName></Paper>. The para-aminobenzyloxycarbonyl (PABC) self-immolative spacer, first developed in the early 1980s for prodrug design, has become a cornerstone of ADC linker technology, particularly for MMAE-conjugated ADCs <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper>. Following enzymatic cleavage in the lysosomal compartment, the PABC spacer in structures like vc-PAB-MMAE undergoes a 1,6-elimination reaction that facilitates the release of free, untethered payload intracellularly <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper>. This system has demonstrated superior plasma stability and improved toxicity profiles compared to earlier cleavable linker generations such as pH-sensitive hydrazone linkers or reducible disulfide linkers <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper>.\n\nRecent refinements in self-immolative chemistry include the development of specialized peptide sequences that enhance cleavage efficiency. For example, replacing the traditional Val-Ala-PABC linker with Gly-Pro-Leu-Gly-PABC (GPLG-PABC) in small molecule-drug conjugates has demonstrated a four-fold improvement in anti-tumor potency across various cancer cell lines <Paper corpusId=\"259682773\" paperTitle=\"(Zambra et al., 2023)\" isShortName></Paper>. This illustrates how even subtle modifications to peptide composition can significantly impact therapeutic outcomes.\n\nA major breakthrough in self-immolative linker technology came with Pillow et al.'s development of sophisticated spacer chemistry enabling direct conjugation of cytotoxic payloads to engineered cysteine residues <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper> <Paper corpusId=\"15129484\" paperTitle=\"(Pillow et al., 2016)\" isShortName></Paper>. This approach facilitates stable disulfide bridges that enhance plasma pharmacokinetics while allowing rapid traceless release of free payloads inside target cells. Notably, this technology improved the tolerability of PBD-ADCs compared to conventional peptide-PABC linker systems while maintaining similar in vivo potency <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper>.\n\nThe development of thiol-responsive linker systems represents another advancement in self-immolative technology. Walther et al. recently described a versatile and tunable system using thiovinylketones that relies on conjugate addition-elimination mechanisms for traceless therapeutic release <Paper corpusId=\"270450900\" paperTitle=\"(Walther et al., 2024)\" isShortName></Paper>. This approach has demonstrated effectiveness in creating thiol-cleavable antibiotic prodrugs and antibody-drug conjugates <Paper corpusId=\"270450900\" paperTitle=\"(Walther et al., 2024)\" isShortName></Paper>.\n\nAdditionally, innovative cleavable zwitterionic linker strategies utilizing tandem 1,6-1,2-elimination of benzyl \u03b1-ammonium carbamates (BACs) have emerged <Paper corpusId=\"274858190\" paperTitle=\"(Li et al., 2024)\" isShortName></Paper>. This design combines two fundamental chemistries: upon trigger cleavage, 1,6-elimination reveals a nitrogen lone pair that undergoes spontaneous 1,2-elimination to release the payload <Paper corpusId=\"274858190\" paperTitle=\"(Li et al., 2024)\" isShortName></Paper>. Importantly, these zwitterionic functional groups effectively shield payload hydrophobicity while maintaining neutral net charge, improving in vivo targeting performance <Paper corpusId=\"274858190\" paperTitle=\"(Li et al., 2024)\" isShortName></Paper>.\n\nThese advancements in self-immolative linker chemistry collectively demonstrate how precise engineering of the cleavage mechanism can enhance ADC stability, improve pharmacokinetics, reduce off-target effects, and ultimately increase therapeutic efficacy. The continued refinement of these technologies addresses key challenges in ADC development related to balancing systemic stability with efficient intracellular drug release.", "citations": [{"id": "(Parashar et al., 2024)", "paper": {"corpus_id": 273979041, "title": "Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy", "year": 2024, "venue": "Discover Oncology", "authors": [{"name": "Ashish Kumar Parashar", "authorId": "2256891951"}, {"name": "G. Saraogi", "authorId": "11995113"}, {"name": "Pushpendra Kumar Jain", "authorId": "2330371554"}, {"name": "B. Kurmi", "authorId": "12604174"}, {"name": "Vivek Shrivastava", "authorId": "2330302884"}, {"name": "Vandana Arora", "authorId": "2259667676"}], "n_citations": 11}, "snippets": ["Cleavable linkers are designed to be stable in the bloodstream to prevent premature drug release. Once they reach the target site, such as a tumor, they can be cleaved through various mechanisms. For instance, linkers can be pH-sensitive, cleaving in the acidic environment of tumors or inflamed tissue. Alternatively, they can be enzyme-sensitive, breaking down in the presence of certain enzymes overexpressed in disease states [70,71].\n\nSelf-Immolative linker undergoes a cascade of chemical reactions triggered by a stimulus (like an enzyme or pH change), resulting in the complete breakdown of the linker and release of the drug [72]. This design allows for a more precise and complete release of the therapeutic agent."], "score": 0.90771484375}, {"id": "(Lu et al., 2016)", "paper": {"corpus_id": 18023696, "title": "Linkers Having a Crucial Role in Antibody\u2013Drug Conjugates", "year": 2016, "venue": "International Journal of Molecular Sciences", "authors": [{"name": "Jun Lu", "authorId": "49301713"}, {"name": "Feng Jiang", "authorId": "2069981623"}, {"name": "Aiping Lu", "authorId": "2086739714"}, {"name": "Ge Zhang", "authorId": "144336463"}], "n_citations": 223}, "snippets": ["Antibody\u2013drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, enhancing the therapeutic parameter of the cytotoxic drug and reducing the possibility of systemic cytotoxicity. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs\u2019 stability during the preparation and storage stages of the ADCs and during the systemic circulation period. The design of linkers for ADCs is a challenge in terms of extracellular stability and intracellular release, and intracellular circumstances, such as the acid environment, the reducing environment and cathepsin, are considered as the catalysts to activate the triggers for initiating the cleavage of ADCs. This review discusses the linkers used in the clinical and marketing stages for ADCs and details the fracture modes of the linkers for the further development of ADCs."], "score": 0.0}, {"id": "(Dosio et al., 2011)", "paper": {"corpus_id": 2862021, "title": "Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components", "year": 2011, "venue": "Toxins", "authors": [{"name": "F. Dosio", "authorId": "6959329"}, {"name": "P. Brusa", "authorId": "6997698"}, {"name": "L. Cattel", "authorId": "6233274"}], "n_citations": 148}, "snippets": ["Immunotoxins and antibody-drug conjugates are protein-based drugs combining a target-specific binding domain with a cytotoxic domain. Such compounds are potentially therapeutic against diseases including cancer, and several clinical trials have shown encouraging results. Although the targeted elimination of malignant cells is an elegant concept, there are numerous practical challenges that limit conjugates\u2019 therapeutic use, including inefficient cellular uptake, low cytotoxicity, and off-target effects. During the preparation of immunoconjugates by chemical synthesis, the choice of the hinge component joining the two building blocks is of paramount importance: the conjugate must remain stable in vivo but must afford efficient release of the toxic moiety when the target is reached. Vast efforts have been made, and the present article reviews strategies employed in developing immunoconjugates, focusing on the evolution of chemical linkers."], "score": 0.0}, {"id": "(Nguyen et al., 2023)", "paper": {"corpus_id": 256296397, "title": "Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability", "year": 2023, "venue": "Cancers", "authors": [{"name": "T. D. Nguyen", "authorId": "2203039174"}, {"name": "Brandon M Bordeau", "authorId": "13358952"}, {"name": "J. Balthasar", "authorId": "5759028"}], "n_citations": 157}, "snippets": ["The advancement of self-immolative linker chemistry has also improved the stability and tolerability of ADCs utilizing cleavable linkers. In the early 1980s, the paraaminobenzyloxycarbonyl (PABC) self-immolate linker chemistry was developed by Carl et al. for use in prodrug design (Carl et al., 1981). Since then, the PABC linker type has been extensively utilized in ADC linker technology, particularly for MMAE-conjugated ADC. Upon cleavage by lysosomal enzymes after ADC internalization into the target cells, the PABC spacer in the vc-PAB-MMAE linker/payload goes through a cascade of disassembly reactions and facilitates the release of untethered MMAE intracellularly [197]. The vc-PABC linker exhibits superior plasma stability and improved toxicity profile compared to the earlier cleavable linker generations, such as the pH-sensitive hydrazone linker used in calicheamicin-based ADCs or disulfide reducible linker used in DM1-based ADCs (Polakis, 2016)", "Recently, Pillow et al. have developed sophisticated self-immolative spacer chemistry that enabled direct conjugation of a cytotoxic payload to engineered cysteine residues (Pillow et al., 2016). This spacer facilitates a stable disulfide bridge, leading to enhanced plasma PK while allowing a rapid traceless release of free payloads intracellularly. This technology improved the tolerability of PBD-ADCs compared to the conventional peptide-PABC linker technology (Pillow et al., 2017). In this study, both the conventional peptide-ADC and the self-immolative disulfide-ADC displayed similar in vivo potency."], "score": 0.84765625}, {"id": "(Zambra et al., 2023)", "paper": {"corpus_id": 259682773, "title": "Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker", "year": 2023, "venue": "Frontiers in Pharmacology", "authors": [{"name": "M. Zambra", "authorId": "2065831065"}, {"name": "Ivan Ran\u0111elovi\u0107", "authorId": "11474948"}, {"name": "Francesco Talarico", "authorId": "2222523572"}, {"name": "Adina Borb\u00e9ly", "authorId": "48989363"}, {"name": "L. Svajda", "authorId": "2165250846"}, {"name": "J. T\u00f3v\u00e1ri", "authorId": "4723217"}, {"name": "G. Mez\u0151", "authorId": "5608068"}, {"name": "Lizeth Bodero", "authorId": "12700782"}, {"name": "Sveva Colombo", "authorId": "2222518746"}, {"name": "F. Arrigoni", "authorId": "40186464"}, {"name": "Elettra Fasola", "authorId": "2196227593"}, {"name": "S. Gazzola", "authorId": "47597460"}, {"name": "U. Piarulli", "authorId": "6179735"}], "n_citations": 1}, "snippets": ["Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs) represent successful examples of targeted drug-delivery technologies for overcoming unwanted side effects of conventional chemotherapy in cancer treatment. In both strategies, a cytotoxic payload is connected to the tumor homing moiety through a linker that releases the drug inside or in proximity of the tumor cell, and that represents a key component for the final therapeutic effect of the conjugate. Here, we show that the replacement of the Val-Ala-p-aminobenzyloxycarbamate linker with the Gly-Pro-Leu-Gly-p-aminobenzyloxycarbamate (GPLG-PABC) sequence as enzymatically cleavable linker in the SMDC bearing the cyclo[DKP-isoDGR] \u03b1V\u03b23 integrin ligand as tumor homing moiety and the monomethyl auristatin E (MMAE) as cytotoxic payload led to a 4-fold more potent anti-tumoral effect of the final conjugate on different cancer cell lines."], "score": 0.69873046875}, {"id": "(Pillow et al., 2016)", "paper": {"corpus_id": 15129484, "title": "Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates", "year": 2016, "venue": "Chemical Science", "authors": [{"name": "Thomas H. Pillow", "authorId": "5994310"}, {"name": "J. Sadowsky", "authorId": "145454705"}, {"name": "Donglu Zhang", "authorId": "46335256"}, {"name": "Shang\u2010Fan Yu", "authorId": "66957769"}, {"name": "Geoffrey Del Rosario", "authorId": "3871772"}, {"name": "Keyang Xu", "authorId": "2931245"}, {"name": "Jintang He", "authorId": "6011389"}, {"name": "S. Bhakta", "authorId": "34341006"}, {"name": "Rachana Ohri", "authorId": "3050148"}, {"name": "K. Kozak", "authorId": "39576252"}, {"name": "E. Ha", "authorId": "153200053"}, {"name": "Jagath R Junutula", "authorId": "6830539"}, {"name": "J. Flygare", "authorId": "5671604"}], "n_citations": 74}, "snippets": ["A novel bioconjugation strategy utilizes a disulfide bond to site-specifically couple a small molecule drug to an antibody, enabling both high circulation stability and quick intracellular release."], "score": 0.0}, {"id": "(Walther et al., 2024)", "paper": {"corpus_id": 270450900, "title": "Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs", "year": 2024, "venue": "Chemical Communications", "authors": [{"name": "Raoul Walther", "authorId": "39607260"}, {"name": "Mahri Park", "authorId": "2306475872"}, {"name": "Nicola Ashman", "authorId": "2178868616"}, {"name": "Martin Welch", "authorId": "2293585024"}, {"name": "Jason S Carroll", "authorId": "2300445797"}, {"name": "David R Spring", "authorId": "2300442974"}], "n_citations": 1}, "snippets": ["We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, which relies on the conjugate addition\u2013elimination mechanism of Michael acceptors for the traceless release of therapeutics. In a proof-of-principle study, we translate our findings to exhibit potent thiol-cleavable antibiotic prodrugs and antibody\u2013drug conjugates."], "score": 0.89501953125}, {"id": "(Li et al., 2024)", "paper": {"corpus_id": 274858190, "title": "Benzyl Ammonium Carbamates Undergo Two\u2010Step Linker Cleavage and Improve the Properties of Antibody Conjugates", "year": 2024, "venue": "Angewandte Chemie", "authors": [{"name": "Xiaoyi Li", "authorId": "2336768595"}, {"name": "Nimit L. Patel", "authorId": "47963510"}, {"name": "J. Kalen", "authorId": "3790172"}, {"name": "M. Schnermann", "authorId": "2212001"}], "n_citations": 2}, "snippets": ["Targeted drug delivery strategies combine a targeting agent and a payload molecule through a cleavable linker. [1,2] [5] The success of an ADC depends on the careful selection of appropriate payloads, optimization of antibody characteristics, and the use of linkers that cleave only after target engagement. [6,7] 10] An appealing strategy is to engineer the linker domain to improve the overall physical properties of the ADC.\n\nExisting linkers often rely on the self-immolative paraamino benzyl (PAB) spacer unit, which was first introduced for biological applications by Katzenellenbogen in 1981. [11] ased on an efficient and general 1,6-elimination (Figure 1A), this approach has been widely used to create cleavable linkers that respond to various stimuli. [12] 20][21][22][23] A critical insight to emerge from these studies is that charged, but net neutral (i.e. zwitterionic) functional groups can effectively shield the hydrophobicity of the payload and improve in vivo targeting performance.\n\nHerein, we detail a cleavable zwitterionic linker strategy utilizing the tandem 1,6-1,2-elimination of benzyl \u03b1ammonium carbamates (BACs). This design was inspired by prior examples that applied the individual reaction components. The 1,6-elimination of quaternary amines has been applied to prepare ADCs with tertiary-and heteroarylamine payloads. [28,29] [32] In this work, we fuse these two fundamental chemistries such that upon trigger cleavage, 1,6-elimination unveils a nitrogen lone pair that undergoes spontaneous 1,2elimination to release the payload (Figure 1B)."], "score": 0.8974609375}], "table": null}, {"title": "Traceless Linker Design Innovations", "tldr": "Traceless linker designs allow for complete removal of the linking structure during payload release, ensuring unmodified therapeutics reach their targets without residual chemical modifications. Recent innovations include disulfide-based systems, thiovinylketone linkers, and exolinkers that improve stability while enabling efficient payload release. (5 sources)", "text": "\nTraceless linker technologies represent a significant advancement in ADC development, focusing on complete linker disassembly upon cleavage to release therapeutics in their original, unmodified form. This approach ensures maximum drug efficacy by preserving the payload's native chemical structure while maintaining stability in circulation. The concept of \"tracelessly\" releasing payloads has become increasingly important as researchers recognize that even small chemical modifications can impact therapeutic potency and pharmacokinetic properties <Paper corpusId=\"256648091\" paperTitle=\"(Cossu et al., 2023)\" isShortName></Paper>.\n\nA breakthrough in traceless linker technology came with Pillow et al.'s development of sophisticated self-immolative spacer chemistry that enables direct conjugation of cytotoxic payloads to engineered cysteine residues on antibodies <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper> <Paper corpusId=\"15129484\" paperTitle=\"(Pillow et al., 2016)\" isShortName></Paper>. This innovative approach facilitates stable disulfide bridges that significantly enhance plasma pharmacokinetics while allowing rapid and complete release of unmodified payloads within target cells. Importantly, this technology has demonstrated improved tolerability for PBD-ADCs compared to conventional peptide-PABC linker systems while maintaining comparable in vivo potency <Paper corpusId=\"256296397\" paperTitle=\"(Nguyen et al., 2023)\" isShortName></Paper>.\n\nMore recently, Walther et al. introduced a versatile thiol-responsive linker system using thiovinylketones that operates through a conjugate addition-elimination mechanism. This approach enables the traceless release of therapeutic agents upon exposure to thiol-rich environments such as those found inside cancer cells. The system's versatility has been demonstrated in both thiol-cleavable antibiotic prodrugs and antibody-drug conjugates, offering a new platform for controlled payload delivery <Paper corpusId=\"270450900\" paperTitle=\"(Walther et al., 2024)\" isShortName></Paper>.\n\nAnother innovative approach in traceless linker design is the \"exolinker\" concept introduced by Watanabe et al. This design repositions the cleavable peptide linker at the exo position of the p-aminobenzylcarbamate moiety, representing an advancement over conventional linear linkers. By incorporating hydrophilic components such as glutamic acid, this approach addresses limitations of traditional Val-Cit platforms while improving ADC stability and performance. Exolinker ADCs have demonstrated reduced premature payload release, increased drug-to-antibody ratios, and enhanced stability in the presence of various enzymes including carboxylesterases and human neutrophil elastase <Paper corpusId=\"273373628\" paperTitle=\"(Watanabe et al., 2024)\" isShortName></Paper>.\n\nThese traceless linker innovations collectively address key challenges in ADC development by improving circulation stability while ensuring efficient and complete payload release at target sites. The ability to deliver unmodified therapeutics without residual chemical modifications represents an important advancement in maximizing the therapeutic potential of antibody-drug conjugates.", "citations": [{"id": "(Cossu et al., 2023)", "paper": {"corpus_id": 256648091, "title": "Multimeric RGD-Based Strategies for Selective Drug Delivery to Tumor Tissues", "year": 2023, "venue": "Pharmaceutics", "authors": [{"name": "Jordan Cossu", "authorId": "2204925801"}, {"name": "Fabien Thoreau", "authorId": "16305385"}, {"name": "D. Boturyn", "authorId": "3594269"}], "n_citations": 22}, "snippets": ["The linker must then be wisely selected accordingly to multiple features-whether the targeted payload is required to be released, in a traceless fashion or not, in intra-or extracellular media in a specific cellular compartment, as well as the propensity of a ligand to trigger internalization or not.\n\nFor the purpose of this review, we focus on cleavable linkers. After a brief listing of the main families of cleavable linkers illustrated with RGD applications, a deeper emphasis is made on cleavable linkers employed for multimeric RGD-based drug delivery. The first large family of cleavable linkers is made of enzyme-sensitive linkers. Among them, a distinction can be made between linkers that encompass a peptide sequence as a cleavage site (peptidase substrate) and others, as depicted below."], "score": 0.8408203125}, {"id": "(Nguyen et al., 2023)", "paper": {"corpus_id": 256296397, "title": "Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability", "year": 2023, "venue": "Cancers", "authors": [{"name": "T. D. Nguyen", "authorId": "2203039174"}, {"name": "Brandon M Bordeau", "authorId": "13358952"}, {"name": "J. Balthasar", "authorId": "5759028"}], "n_citations": 157}, "snippets": ["The advancement of self-immolative linker chemistry has also improved the stability and tolerability of ADCs utilizing cleavable linkers. In the early 1980s, the paraaminobenzyloxycarbonyl (PABC) self-immolate linker chemistry was developed by Carl et al. for use in prodrug design (Carl et al., 1981). Since then, the PABC linker type has been extensively utilized in ADC linker technology, particularly for MMAE-conjugated ADC. Upon cleavage by lysosomal enzymes after ADC internalization into the target cells, the PABC spacer in the vc-PAB-MMAE linker/payload goes through a cascade of disassembly reactions and facilitates the release of untethered MMAE intracellularly [197]. The vc-PABC linker exhibits superior plasma stability and improved toxicity profile compared to the earlier cleavable linker generations, such as the pH-sensitive hydrazone linker used in calicheamicin-based ADCs or disulfide reducible linker used in DM1-based ADCs (Polakis, 2016)", "Recently, Pillow et al. have developed sophisticated self-immolative spacer chemistry that enabled direct conjugation of a cytotoxic payload to engineered cysteine residues (Pillow et al., 2016). This spacer facilitates a stable disulfide bridge, leading to enhanced plasma PK while allowing a rapid traceless release of free payloads intracellularly. This technology improved the tolerability of PBD-ADCs compared to the conventional peptide-PABC linker technology (Pillow et al., 2017). In this study, both the conventional peptide-ADC and the self-immolative disulfide-ADC displayed similar in vivo potency."], "score": 0.84765625}, {"id": "(Pillow et al., 2016)", "paper": {"corpus_id": 15129484, "title": "Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates", "year": 2016, "venue": "Chemical Science", "authors": [{"name": "Thomas H. Pillow", "authorId": "5994310"}, {"name": "J. Sadowsky", "authorId": "145454705"}, {"name": "Donglu Zhang", "authorId": "46335256"}, {"name": "Shang\u2010Fan Yu", "authorId": "66957769"}, {"name": "Geoffrey Del Rosario", "authorId": "3871772"}, {"name": "Keyang Xu", "authorId": "2931245"}, {"name": "Jintang He", "authorId": "6011389"}, {"name": "S. Bhakta", "authorId": "34341006"}, {"name": "Rachana Ohri", "authorId": "3050148"}, {"name": "K. Kozak", "authorId": "39576252"}, {"name": "E. Ha", "authorId": "153200053"}, {"name": "Jagath R Junutula", "authorId": "6830539"}, {"name": "J. Flygare", "authorId": "5671604"}], "n_citations": 74}, "snippets": ["A novel bioconjugation strategy utilizes a disulfide bond to site-specifically couple a small molecule drug to an antibody, enabling both high circulation stability and quick intracellular release."], "score": 0.0}, {"id": "(Walther et al., 2024)", "paper": {"corpus_id": 270450900, "title": "Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs", "year": 2024, "venue": "Chemical Communications", "authors": [{"name": "Raoul Walther", "authorId": "39607260"}, {"name": "Mahri Park", "authorId": "2306475872"}, {"name": "Nicola Ashman", "authorId": "2178868616"}, {"name": "Martin Welch", "authorId": "2293585024"}, {"name": "Jason S Carroll", "authorId": "2300445797"}, {"name": "David R Spring", "authorId": "2300442974"}], "n_citations": 1}, "snippets": ["We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, which relies on the conjugate addition\u2013elimination mechanism of Michael acceptors for the traceless release of therapeutics. In a proof-of-principle study, we translate our findings to exhibit potent thiol-cleavable antibiotic prodrugs and antibody\u2013drug conjugates."], "score": 0.89501953125}, {"id": "(Watanabe et al., 2024)", "paper": {"corpus_id": 273373628, "title": "Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody\u2013Drug Conjugates", "year": 2024, "venue": "Journal of Medicinal Chemistry", "authors": [{"name": "Tomohiro Watanabe", "authorId": "2211359897"}, {"name": "Naoko Arashida", "authorId": "48879931"}, {"name": "Tomohiro Fujii", "authorId": "2260377633"}, {"name": "Natsuki Shikida", "authorId": "80082264"}, {"name": "Kenichiro Ito", "authorId": "2275570250"}, {"name": "Kazutaka Shimbo", "authorId": "2297365936"}, {"name": "Takuya Seki", "authorId": "1720876232"}, {"name": "Yusuke Iwai", "authorId": "2211287902"}, {"name": "Ryusuke Hirama", "authorId": "14702220"}, {"name": "Noriko Hatada", "authorId": "48950037"}, {"name": "Akira Nakayama", "authorId": "2297369013"}, {"name": "T. Okuzumi", "authorId": "6117942"}, {"name": "Yutaka Matsuda", "authorId": "2214891177"}], "n_citations": 12}, "snippets": ["This study introduces an exolinker approach, repositioning the cleavable peptide linker at the exo position of the p-aminobenzylcarbamate moiety, as an advancement over conventional linear linkers. This design, which incorporates hydrophilic glutamic acid, addresses the limitations of the Val-Cit platform and improves the ADC in vivo profiles. In vitro and in vivo evaluations showed that exolinker ADCs reduced premature payload release, increased drug-to-antibody ratios, and avoided significant aggregation, even with hydrophobic payloads. Furthermore, the payload remained stably attached to the ADC even in the presence of enzymes like carboxylesterases and human neutrophil elastase, indicating the potential for a favorable safety profile."], "score": 0.9326171875}], "table": null}, {"title": "Hydrophilic and Zwitterionic Linker Developments", "tldr": "Hydrophilic and zwitterionic linkers represent an important advancement in ADC design by counterbalancing payload hydrophobicity, which improves circulation stability, reduces aggregation, and minimizes off-target toxicity. These innovative linker designs incorporate charged groups, PEG chains, sulfonate moieties, and specialized zwitterionic structures to enhance ADC pharmacokinetics while maintaining efficient payload delivery. (8 sources)", "text": "\nThe development of hydrophilic and zwitterionic linkers has emerged as a critical innovation in addressing key limitations of early ADC designs, particularly those related to payload hydrophobicity. Highly hydrophobic payloads can destabilize the native antibody structure and increase self-association and aggregation propensity, which directly impacts ADC stability, safety, and efficacy <Paper corpusId=\"44081710\" paperTitle=\"(Buecheler et al., 2018)\" isShortName></Paper>. This recognition has driven significant research into linker chemistries that can balance payload hydrophobicity while maintaining stability in circulation.\n\nSeveral hydrophilic linker technologies have been developed to improve ADC stability and pharmacokinetics. These include sulfonate-containing linkers, polyethylene glycol (PEG) chains, polysarcosine (PSAR), and even DNA-based linkers, all of which have demonstrated significant improvements in ADC stability and pharmacokinetic profiles <Paper corpusId=\"255967333\" paperTitle=\"(Conilh et al., 2023)\" isShortName></Paper>. The incorporation of these hydrophilic elements has led to less toxic and more active ADCs by reducing nonspecific uptake and improving circulation stability <Paper corpusId=\"255967333\" paperTitle=\"(Conilh et al., 2023)\" isShortName></Paper> <Paper corpusId=\"11154466\" paperTitle=\"(Ratanji et al., 2013)\" isShortName></Paper>.\n\nRecent advances in non-cleavable linker technology include SMCC (Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) linkers and MD (Molecular Dynamics) linkers. SMCC linkers incorporate a cyclo-nucleic acid ring that reduces hydrolysis rates at high pH, enhancing stability while preserving antibody specificity. MD linkers further improve on this design by substituting the cyclo-nucleic acid ring with 1,3-dioxolein, which contains two oxygen atoms that enhance linker hydrophilicity and stability <Paper corpusId=\"265004291\" paperTitle=\"(Song et al., 2023)\" isShortName></Paper>.\n\nEnzyme-responsive hydrophilic linkers represent another area of innovation. \u03b2-glucuronidase and \u03b2-galactosidase responsive linkers have been developed that maintain stability in circulation but undergo enzymatic cleavage in lysosomes <Paper corpusId=\"265004291\" paperTitle=\"(Song et al., 2023)\" isShortName></Paper>. For example, arylsulfate-containing ADC linkers have been shown to be cleaved by lysosomal sulfatase enzymes, resulting in traceless payload release while avoiding stability issues associated with dipeptide linkers <Paper corpusId=\"212949379\" paperTitle=\"(Bargh et al., 2020)\" isShortName></Paper>. These linkers demonstrate superior stability, solubility, and synthetic tractability compared to widely used dipeptidic linkers.\n\nThe incorporation of PEG spacers has also proven beneficial in enzyme-responsive linker designs. Research has shown that conjugates bearing a PEG4 spacer can effectively inhibit the proliferation of target cells at low nanomolar concentrations when used with \u03b2-glucuronidase-responsive linkers <Paper corpusId=\"131778513\" paperTitle=\"(Rivas et al., 2019)\" isShortName></Paper>. Similarly, 3-O-sulfo-\u03b2-galactose linkers, which are sequentially cleaved by two lysosomal enzymes (arylsulfatase A and \u03b2-galactosidase), have demonstrated excellent cytotoxicity and selectivity when used in HER2-targeting ADCs <Paper corpusId=\"232159000\" paperTitle=\"(Bargh et al., 2021)\" isShortName></Paper>.\n\nPerhaps most innovative are zwitterionic linker strategies that utilize charged but net-neutral functional groups to effectively shield payload hydrophobicity. A recent advancement in this area involves cleavable zwitterionic linkers utilizing tandem 1,6-1,2-elimination of benzyl \u03b1-ammonium carbamates (BACs). This design combines two fundamental chemistries: upon trigger cleavage, 1,6-elimination reveals a nitrogen lone pair that subsequently undergoes spontaneous 1,2-elimination to release the payload <Paper corpusId=\"274858190\" paperTitle=\"(Li et al., 2024)\" isShortName></Paper>. This approach represents a significant improvement in balancing the hydrophobicity of payloads while maintaining efficient release mechanisms.\n\nThe evolution of hydrophilic and zwitterionic linker technologies has significantly advanced ADC development by addressing key challenges related to stability, aggregation, and off-target toxicity. These linker designs effectively balance the hydrophobicity of cytotoxic payloads while maintaining efficient release mechanisms, ultimately improving the therapeutic window of antibody-drug conjugates.", "citations": [{"id": "(Buecheler et al., 2018)", "paper": {"corpus_id": 44081710, "title": "Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.", "year": 2018, "venue": "Molecular Pharmaceutics", "authors": [{"name": "J. Buecheler", "authorId": "47464908"}, {"name": "Matthias Winzer", "authorId": "30774798"}, {"name": "Jason Tonillo", "authorId": "48304628"}, {"name": "Christian Weber", "authorId": "2064774550"}, {"name": "H. Gieseler", "authorId": "5985951"}], "n_citations": 68}, "snippets": ["In silico screening of toxin payloads typically employed in ADCs revealed a wide range of hydrophobicities and sizes as measured by log P and topological polar surface area (tPSA) values. These descriptors were used to identify three nontoxic surrogate payloads that encompass the range of hydrophobicity defined by the ADC toxin training set. The uniform drug to antibody ratio (DAR) ADCs were prepared for each surrogate payload by conjugation to the interchain cysteine residues of a model IgG1 subtype mAb. Linkage of these surrogate payloads to a common mAb with a matched DAR value allowed for preliminary analytical interrogation of the influence of payload hydrophobicity on global structure, self-association, and aggregation properties. The results of differential scanning fluorimetry and dynamic light scattering experiments clearly revealed a direct correlation between the destabilization of the native mAb structure and the increasing payload hydrophobicity. Also, self-association/aggregation propensity examined by self-interaction biolayer interferometry or size exclusion HPLC was consistent with increased conversion of the monomeric mAb to higher order aggregated species, with the degree of conversion directly proportional to the payload hydrophobicity. In summary, these findings prove that the payload-dependent structure destabilization and enhanced propensity to self-associate/aggregate driven by the increasing payload hydrophobicity contribute to reduced ADC stability and more complex behavior when assessing exposure and safety/efficacy relationships."], "score": 0.0}, {"id": "(Conilh et al., 2023)", "paper": {"corpus_id": 255967333, "title": "Payload diversification: a key step in the development of antibody\u2013drug conjugates", "year": 2023, "venue": "Journal of Hematology & Oncology", "authors": [{"name": "L. Conilh", "authorId": "1768154554"}, {"name": "L. Sad\u00edlkov\u00e1", "authorId": "3561670"}, {"name": "W. Viricel", "authorId": "11233897"}, {"name": "C. Dumontet", "authorId": "32058344"}], "n_citations": 103}, "snippets": ["The linker plays a major role in ADC design since it strongly impacts on the safety, potency and activity of the ADC. Most importantly, the linker is expected to remain stable in circulation to avoid premature detachment of the drug while allowing its release within the targeted cell. Two categories of linkers have been developed and can be distinguished based on their cleavability. Cleavable linkers are either sensitive to pH for hydrazone linkers, to glutathione or disulfide isomerase for disulfide linkers and to proteases such as cathepsin B for dipeptide bonds. Non-cleavable linkers rely on lysosomal degradation of the antibody moiety, thereby conserving at least one amino acid, most commonly lysine or cysteine, attached to the payload-linker complex", "recent interest in linker design improvement has led to the development of hydrophilic linkers to balance payload hydrophobicity (Buecheler et al., 2018)(Ratanji et al., 2013)(Lyon et al., 2015)(Hamblett et al., 2004). Sulfonate, polyethylene glycol (PEG), polysarcosine (PSAR) or more recently DNA-based linkers have significantly improved ADC stability and pharmacokinetics, leading to less toxic and more active ADCs [30][31][32][33][34][35][36][37]."], "score": 0.88720703125}, {"id": "(Ratanji et al., 2013)", "paper": {"corpus_id": 11154466, "title": "Immunogenicity of therapeutic proteins: Influence of aggregation", "year": 2013, "venue": "Journal of Immunotoxicology", "authors": [{"name": "Kirsty D. Ratanji", "authorId": "6180320"}, {"name": "J. Derrick", "authorId": "40127110"}, {"name": "R. Dearman", "authorId": "3743932"}, {"name": "I. Kimber", "authorId": "4556917"}], "n_citations": 461}, "snippets": ["Abstract The elicitation of anti-drug antibodies (ADA) against biotherapeutics can have detrimental effects on drug safety, efficacy, and pharmacokinetics. The immunogenicity of biotherapeutics is, therefore, an important issue. There is evidence that protein aggregation can result in enhanced immunogenicity; however, the precise immunological and biochemical mechanisms responsible are poorly defined. In the context of biotherapeutic drug development and safety assessment, understanding the mechanisms underlying aggregate immunogenicity is of considerable interest. This review provides an overview of the phenomenon of protein aggregation, the production of unwanted aggregates during bioprocessing, and how the immune response to aggregated protein differs from that provoked by non-aggregated protein. Of particular interest is the nature of the interaction of aggregates with the immune system and how subsequent ADA responses are induced. Pathways considered here include \u2018classical\u2019 activation of the immune system involving antigen presenting cells and, alternatively, the breakdown of B-cell tolerance. Additionally, methods available to screen for aggregation and immunogenicity will be described. With an increased understanding of aggregation-enhanced immune responses, it may be possible to develop improved manufacturing and screening processes to avoid, or at least reduce, the problems associated with ADA."], "score": 0.0}, {"id": "(Song et al., 2023)", "paper": {"corpus_id": 265004291, "title": "Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy", "year": 2023, "venue": "Antibodies", "authors": [{"name": "Chi Hun Song", "authorId": "2254053096"}, {"name": "M. Jeong", "authorId": "2295383783"}, {"name": "Hyukmin In", "authorId": "2265282226"}, {"name": "Ji Hoe Kim", "authorId": "2248450105"}, {"name": "Chih-Wei Lin", "authorId": "2265361961"}, {"name": "Kyung Ho Han", "authorId": "2197707426"}], "n_citations": 13}, "snippets": ["Recent advancements have given rise to non-cleavable linkers, notably the SMCC (Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) linkers and MD (Molecular Dynamics) linkers, which are currently in development. The hydrophilic nature of linker plays a pivotal role in diminishing nonspecific uptake or off-target toxicity of payload. SMCC linkers incorporate a cyclo-nucleic acid ring that reduces the antibody conjugate's hydrolysis rate at high pH levels, thus bolstering stability while preserving antibody specificity. On the other hand, MD linkers substitute the cyclo-nucleic acid ring of SMCC linkers with 1,3-dioxolein, enhancing linker hydrophilicity and stability due to the presence of two oxygen atoms within the 1,3-dioxolein ring (Figure 4)", "proved Hodgkin's lymphoma drug brentuximab vedotin using an CD30 antibody with a peptide cleavable linker and MMAE (Moskowitz et al., 2015). Furthermore, various enzyme-based linkers, such as \u03b2-glucuronidase and \u03b2-galactosidase linkers, have been developed (Bargh et al., 2020)(Jackson et al., 2022)(Bargh et al., 2021)(Rivas et al., 2019) (Figure 4). These are degraded by enzymes present in lysosomes, rendering them more stable in the bloodstream compared to chemically cleavable linkers."], "score": 0.7060546875}, {"id": "(Bargh et al., 2020)", "paper": {"corpus_id": 212949379, "title": "Sulfatase-cleavable linkers for antibody-drug conjugates\u2020", "year": 2020, "venue": "Chemical Science", "authors": [{"name": "Jonathan D Bargh", "authorId": "150139163"}, {"name": "Stephen J. Walsh", "authorId": "144426411"}, {"name": "Albert Isidro-Llobet", "authorId": "1397914841"}, {"name": "Soleilmane Omarjee", "authorId": "51036872"}, {"name": "J. Carroll", "authorId": "144276847"}, {"name": "D. Spring", "authorId": "1761031"}], "n_citations": 33}, "snippets": ["Antibody-drug conjugates (ADCs) are a class of targeted drug delivery agents combining the cell-selectivity of monoclonal antibodies (mAbs) and the cytotoxicity of small molecules. These two components are joined by a covalent linker, whose nature is critical to the efficacy and safety of the ADC. Enzyme-cleavable dipeptidic linkers have emerged as a particularly effective ADC linker type due to their ability to selectively release the payload in the lysosomes of target cells. However, these linkers have a number of drawbacks, including instability in rodent plasma and their inherently high hydrophobicity. Here we show that arylsulfate-containing ADC linkers are cleaved by lysosomal sulfatase enzymes to tracelessly release their payload, while circumventing the instability problems associated with dipeptide-linkers. When incorporated with trastuzumab and the highly potent monomethyl auristatin E (MMAE) payload, the arylsulfate-containing ADC 2 and ADC 3 were more cytotoxic than the non-cleavable ADC 4 against HER2-positive cells, while maintaining selectivity over HER2-negative cells. We propose that the stability, solubility and synthetic tractability of our arylsulfate linkers make them an attractive new motif for cleavable ADC linkers, with clear benefits over the widely used dipeptidic linkers."], "score": 0.0}, {"id": "(Rivas et al., 2019)", "paper": {"corpus_id": 131778513, "title": "\u03b2-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.", "year": 2019, "venue": "Organic and biomolecular chemistry", "authors": [{"name": "Paula L\u00f3pez Rivas", "authorId": "15058074"}, {"name": "C. M\u00fcller", "authorId": "2087049058"}, {"name": "C. Breunig", "authorId": "2034260820"}, {"name": "Torsten Hechler", "authorId": "34910265"}, {"name": "A. Pahl", "authorId": "152398525"}, {"name": "D. Arosio", "authorId": "5928965"}, {"name": "L. Belvisi", "authorId": "2866792"}, {"name": "L. Pignataro", "authorId": "144633801"}, {"name": "Alberto Dal Corso", "authorId": "12244900"}, {"name": "C. Gennari", "authorId": "39834350"}], "n_citations": 10}, "snippets": ["A non-internalizing \u03b1v\u03b23 integrin ligand was conjugated to the anticancer drug MMAE through a \u03b2-glucuronidase-responsive linker. In the presence of \u03b2-glucuronidase, only the conjugate bearing a PEG4 spacer inhibited the proliferation of integrin-expressing cancer cells at low nanomolar concentrations, indicating important structural requirements for the efficacy of these therapeutics."], "score": 0.0}, {"id": "(Bargh et al., 2021)", "paper": {"corpus_id": 232159000, "title": "A dual-enzyme cleavable linker for antibody-drug conjugates.", "year": 2021, "venue": "Chemical Communications", "authors": [{"name": "Jonathan D Bargh", "authorId": "150139163"}, {"name": "Stephen J. Walsh", "authorId": "144426411"}, {"name": "Nic Ashman", "authorId": "52644483"}, {"name": "Albert Isidro-Llobet", "authorId": "1397914841"}, {"name": "J. Carroll", "authorId": "144276847"}, {"name": "D. Spring", "authorId": "1761031"}], "n_citations": 15}, "snippets": ["A novel enzyme cleavable linker for antibody-drug conjugates is reported. The 3-O-sulfo-\u03b2-galactose linker is cleaved sequentially by two lysosomal enzymes - arylsulfatase A and \u03b2-galactosidase - to release the payload in targeted cells. An \u03b1-HER2 antibody-drug conjugate synthesised using this highly hydrophilic dual-cleavable linker exhibited excellent cytotoxicity and selectivity."], "score": 0.0}, {"id": "(Li et al., 2024)", "paper": {"corpus_id": 274858190, "title": "Benzyl Ammonium Carbamates Undergo Two\u2010Step Linker Cleavage and Improve the Properties of Antibody Conjugates", "year": 2024, "venue": "Angewandte Chemie", "authors": [{"name": "Xiaoyi Li", "authorId": "2336768595"}, {"name": "Nimit L. Patel", "authorId": "47963510"}, {"name": "J. Kalen", "authorId": "3790172"}, {"name": "M. Schnermann", "authorId": "2212001"}], "n_citations": 2}, "snippets": ["Targeted drug delivery strategies combine a targeting agent and a payload molecule through a cleavable linker. [1,2] [5] The success of an ADC depends on the careful selection of appropriate payloads, optimization of antibody characteristics, and the use of linkers that cleave only after target engagement. [6,7] 10] An appealing strategy is to engineer the linker domain to improve the overall physical properties of the ADC.\n\nExisting linkers often rely on the self-immolative paraamino benzyl (PAB) spacer unit, which was first introduced for biological applications by Katzenellenbogen in 1981. [11] ased on an efficient and general 1,6-elimination (Figure 1A), this approach has been widely used to create cleavable linkers that respond to various stimuli. [12] 20][21][22][23] A critical insight to emerge from these studies is that charged, but net neutral (i.e. zwitterionic) functional groups can effectively shield the hydrophobicity of the payload and improve in vivo targeting performance.\n\nHerein, we detail a cleavable zwitterionic linker strategy utilizing the tandem 1,6-1,2-elimination of benzyl \u03b1ammonium carbamates (BACs). This design was inspired by prior examples that applied the individual reaction components. The 1,6-elimination of quaternary amines has been applied to prepare ADCs with tertiary-and heteroarylamine payloads. [28,29] [32] In this work, we fuse these two fundamental chemistries such that upon trigger cleavage, 1,6-elimination unveils a nitrogen lone pair that undergoes spontaneous 1,2elimination to release the payload (Figure 1B)."], "score": 0.8974609375}], "table": null}, {"title": "Specialized Linker Designs: Tandem Linkers and Exolinkers", "tldr": "Tandem linkers and exolinkers represent cutting-edge ADC technologies that address premature payload release through multiple sequential cleavage steps or strategic repositioning of cleavable elements. These innovations improve ADC stability and reduce off-target toxicity while maintaining therapeutic efficacy against cancer cells. (5 sources)", "text": "\nRecent developments in specialized linker technologies have introduced innovative designs that significantly enhance the stability and safety profiles of antibody-drug conjugates. Among these advancements, tandem linkers and exolinkers stand out for their ability to address persistent challenges in ADC development, particularly premature payload release.\n\nTandem cleavable linkers represent a novel approach that requires sequential enzymatic cleavage events to release the cytotoxic payload. These sophisticated designs incorporate a \u03b2-glucuronide moiety that provides protection against extracellular enzymatic degradation during circulation <Paper corpusId=\"269587315\" paperTitle=\"(Takakura et al., 2024)\" isShortName></Paper>. This strategic modification addresses a significant limitation of traditional peptide linkers, which are often vulnerable to cleavage by extracellular enzymes such as elastase, resulting in systemic payload release and off-target toxicity <Paper corpusId=\"269587315\" paperTitle=\"(Takakura et al., 2024)\" isShortName></Paper> <Paper corpusId=\"232191243\" paperTitle=\"(Chuprakov et al., 2021)\" isShortName></Paper>. By requiring two sequential enzymatic cleavage events, tandem linkers effectively reduce premature payload release, thereby minimizing off-target toxicity while maintaining efficient drug delivery to tumor cells <Paper corpusId=\"269587315\" paperTitle=\"(Takakura et al., 2024)\" isShortName></Paper>.\n\nAnother significant advancement is the development of exolinkers, which reposition the cleavable peptide linker at the exo position of the p-aminobenzylcarbamate moiety. This innovative design incorporates hydrophilic components such as glutamic acid to address limitations of conventional Val-Cit platforms <Paper corpusId=\"273373628\" paperTitle=\"(Watanabe et al., 2024)\" isShortName></Paper>. Exolinker ADCs have demonstrated reduced premature payload release, increased drug-to-antibody ratios, and improved stability even with hydrophobic payloads. Notably, these constructs maintain stability in the presence of problematic enzymes including carboxylesterases and human neutrophil elastase, suggesting potential for enhanced safety profiles <Paper corpusId=\"273373628\" paperTitle=\"(Watanabe et al., 2024)\" isShortName></Paper>.\n\nSimilarly, specialized peptide sequences such as glutamic acid-glycine-citrulline (EGCit) linkers have been developed to resist neutrophil protease-mediated degradation while preserving the capacity for traceless drug release. These linkers have demonstrated protection of differentiating human neutrophils without compromising ADC therapeutic efficacy <Paper corpusId=\"250337069\" paperTitle=\"(Ha et al., 2022)\" isShortName></Paper>.\n\nThe development of these specialized linker technologies addresses a critical challenge in ADC therapy: balancing stability in circulation with efficient payload release at target sites. As noted by Balamkundu et al., despite significant advances in linker-payload design leading to increased regulatory approvals, dose-limiting toxicity remains a concern in clinical trials, partly attributable to systemic payload release and suboptimal pharmacokinetic properties <Paper corpusId=\"265324669\" paperTitle=\"(Balamkundu et al., 2023)\" isShortName></Paper>. The introduction of more stable linker systems, particularly those with specific peptide/peptidomimetic sequences, can significantly reduce premature cleavage at non-tumor sites, thereby enhancing ADC safety profiles <Paper corpusId=\"265324669\" paperTitle=\"(Balamkundu et al., 2023)\" isShortName></Paper>.\n\nThese specialized linker designs represent important steps toward addressing persistent challenges in ADC development. By strategically controlling payload release through multiple cleavage steps or optimized linker positioning, tandem linkers and exolinkers contribute to improved stability, reduced off-target toxicity, and enhanced therapeutic indices for ADC therapies.", "citations": [{"id": "(Takakura et al., 2024)", "paper": {"corpus_id": 269587315, "title": "Antibody-drug conjugates in solid tumors; new strategy for cancer therapy", "year": 2024, "venue": "Japanese Journal of Clinical Oncology", "authors": [{"name": "Toshiaki Takakura", "authorId": "2003149438"}, {"name": "T. Shimizu", "authorId": "2107246988"}, {"name": "Nobuyuki Yamamoto", "authorId": "2281575109"}], "n_citations": 3}, "snippets": ["Tandem linker. One drawback associated with cleavable linkers is the potential to release payloads in plasma circulation before tumor targeting. If the payloads are released systemically prematurely, the efficacy of the remaining circulating ADCs may be reduced, leading to off-target toxicity. Tandem cleavable linkers are novel linkers that incorporate a \u03b2-glucuronide moiety and require tandem enzymic cleavage events (Chuprakov et al., 2021). These linkers reduce payloads release during circulation and off-target toxicity."], "score": 0.84814453125}, {"id": "(Chuprakov et al., 2021)", "paper": {"corpus_id": 232191243, "title": "Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates", "year": 2021, "venue": "bioRxiv", "authors": [{"name": "S. Chuprakov", "authorId": "11393961"}, {"name": "A. Ogunkoya", "authorId": "40081339"}, {"name": "Robyn M. Barfield", "authorId": "3877180"}, {"name": "M. Bauzon", "authorId": "5542924"}, {"name": "Colin Hickle", "authorId": "1600414484"}, {"name": "Y. Kim", "authorId": "2536945"}, {"name": "Dominick Yeo", "authorId": "123177617"}, {"name": "Fangjiu Zhang", "authorId": "22049425"}, {"name": "David Rabuka", "authorId": "4705819"}, {"name": "Penelope M. Drake", "authorId": "20720139"}], "n_citations": 36}, "snippets": ["Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody-drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, leading to systemic release of the cytotoxic payload. This action reduces the therapeutic index by causing off-target toxicities that can be dose-limiting. For example, a common side-effect of ADCs made using peptide-cleavable linkers is myelosuppression, including neutropenia. Only a few reports describe methods for optimizing peptide linkers to maintain efficient and potent tumor payload delivery while enhancing circulating stability. Herein, we address these critical limitations through the development of a tandem-cleavage linker strategy, where two sequential enzymatic cleavage events mediate payload release. We prepared dipeptides that are protected from degradation in the circulation by a sterically-encumbering glucuronide moiety. Upon ADC internalization and lysosomal degradation, the monosaccharide is removed and the exposed dipeptide is degraded, liberating the attached payload inside the target cell. We used CD79b-targeted monomethyl auristatin E (MMAE) conjugates as our model system, and compared the stability, efficacy, and tolerability of ADCs made with tandem-cleavage linkers to ADCs made using standard technology with the vedotin linker. The results\u2014where rat studies showed dramatically improved tolerability in the hematopoietic compartment\u2014highlight the role that linker stability plays in efficacy and tolerability, and offer a means of improving an ADC\u2019s therapeutic index for improved patient outcomes."], "score": 0.0}, {"id": "(Watanabe et al., 2024)", "paper": {"corpus_id": 273373628, "title": "Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody\u2013Drug Conjugates", "year": 2024, "venue": "Journal of Medicinal Chemistry", "authors": [{"name": "Tomohiro Watanabe", "authorId": "2211359897"}, {"name": "Naoko Arashida", "authorId": "48879931"}, {"name": "Tomohiro Fujii", "authorId": "2260377633"}, {"name": "Natsuki Shikida", "authorId": "80082264"}, {"name": "Kenichiro Ito", "authorId": "2275570250"}, {"name": "Kazutaka Shimbo", "authorId": "2297365936"}, {"name": "Takuya Seki", "authorId": "1720876232"}, {"name": "Yusuke Iwai", "authorId": "2211287902"}, {"name": "Ryusuke Hirama", "authorId": "14702220"}, {"name": "Noriko Hatada", "authorId": "48950037"}, {"name": "Akira Nakayama", "authorId": "2297369013"}, {"name": "T. Okuzumi", "authorId": "6117942"}, {"name": "Yutaka Matsuda", "authorId": "2214891177"}], "n_citations": 12}, "snippets": ["This study introduces an exolinker approach, repositioning the cleavable peptide linker at the exo position of the p-aminobenzylcarbamate moiety, as an advancement over conventional linear linkers. This design, which incorporates hydrophilic glutamic acid, addresses the limitations of the Val-Cit platform and improves the ADC in vivo profiles. In vitro and in vivo evaluations showed that exolinker ADCs reduced premature payload release, increased drug-to-antibody ratios, and avoided significant aggregation, even with hydrophobic payloads. Furthermore, the payload remained stably attached to the ADC even in the presence of enzymes like carboxylesterases and human neutrophil elastase, indicating the potential for a favorable safety profile."], "score": 0.9326171875}, {"id": "(Ha et al., 2022)", "paper": {"corpus_id": 250337069, "title": "An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates.", "year": 2022, "venue": "Molecular Cancer Therapeutics", "authors": [{"name": "Summer Y Y Ha", "authorId": "116690271"}, {"name": "Y. Anami", "authorId": "48053285"}, {"name": "Chisato M. Yamazaki", "authorId": "15922353"}, {"name": "Wei Xiong", "authorId": "4969405"}, {"name": "Candice M Haase", "authorId": "39947082"}, {"name": "Scott D. Olson", "authorId": "2239205392"}, {"name": "Jangsoon Lee", "authorId": "87342996"}, {"name": "N. Ueno", "authorId": "35425570"}, {"name": "Ningyan Zhang", "authorId": "6283900"}, {"name": "Z. An", "authorId": "1916145"}, {"name": "K. Tsuchikama", "authorId": "47395909"}], "n_citations": 14}, "snippets": ["Here, we report that glutamic acid-glycine-citrulline (EGCit) linkers have the potential to solve this clinical issue without compromising the ability of traceless drug release and ADC therapeutic efficacy. We demonstrate that our EGCit ADC resists neutrophil protease-mediated degradation and spares differentiating human neutrophils."], "score": 0.896484375}, {"id": "(Balamkundu et al., 2023)", "paper": {"corpus_id": 265324669, "title": "Lysosomal-Cleavable Peptide Linkers in Antibody\u2013Drug Conjugates", "year": 2023, "venue": "Biomedicines", "authors": [{"name": "S. Balamkundu", "authorId": "52169581"}, {"name": "Chuan-Fa Liu", "authorId": "2267632374"}], "n_citations": 27}, "snippets": ["The immense research effort put into ADC linker-payload design during the past decade has contributed to a sharp increase in regulatory approvals. However, ADC development still faces dose-limiting toxicity issues during clinical trials, which could be partly attributed to the systemic release of the payload and poor PK properties. The development of more stable linker systems in mouse and rat plasma would accelerate the preclinical evaluation of the ADC drug candidates. In particular, the identification of new peptide/peptidomimetic sequences will allow highly specific cleavage, which can greatly reduce premature cleavage of the linker at non-tumor sites, hence increasing the safety profiles of the ADCs. Obviously, the linker systems reviewed herein apply only to typical ADCs which rely on binding to an internalizing antigen and subsequent receptor-mediated endocytosis to release the payload via lysosomal degradation. Nevertheless, recent years have also seen growing interest in developing an atypical class of ADCs targeting poorly- or non-internalizing antigens on cancer cells or components of surrounding tumor stroma. For these ADCs, the linkers are cleaved extracellularly within the tumor microenvironment to release the payload, which can then diffuse into nearby cancer cells for selective killing."], "score": 0.951171875}], "table": null}, {"title": "Impact of Linker Design on ADC Performance", "tldr": "Linker design significantly influences ADC stability, pharmacokinetics, toxicity profile, and therapeutic efficacy by controlling drug release mechanisms and payload delivery. The choice of optimal linker chemistry must balance circulation stability with efficient payload release and is highly dependent on the specific antibody-target-payload combination. (9 sources)", "text": "\nThe linker component of antibody-drug conjugates critically influences multiple aspects of ADC performance, serving as a key determinant of therapeutic success. Linker design directly impacts conjugate stability, modulates cytotoxic agent release kinetics, and shapes overall pharmacokinetic profiles <Paper corpusId=\"251880235\" paperTitle=\"(Chis et al., 2022)\" isShortName></Paper> <Paper corpusId=\"195879565\" paperTitle=\"(Bargh et al., 2019)\" isShortName></Paper> <Paper corpusId=\"232774369\" paperTitle=\"(Zhong et al., 2021)\" isShortName></Paper> <Paper corpusId=\"238745220\" paperTitle=\"(Lindberg et al., 2021)\" isShortName></Paper>. This multifaceted influence extends to both efficacy and safety outcomes, making linker selection a pivotal decision in ADC development.\n\nThe choice between different linker types entails various performance trade-offs. Cleavable linkers containing disulfide bonds, which are sensitive to intracellular glutathione, may offer advantages for treating specific cancer types including ovarian, head and neck, and lung cancers, where increased tumor glutathione levels have been documented <Paper corpusId=\"276971806\" paperTitle=\"(Buyukgolcigezli et al., 2025)\" isShortName></Paper> <Paper corpusId=\"235213516\" paperTitle=\"(Kostova et al., 2021)\" isShortName></Paper>. Such mechanism-targeted approaches highlight how linker design can be tailored to exploit specific tumor biochemistry.\n\nProtease-cleavable linkers represent another category that balances plasma stability with targeted drug release. These linkers remain intact in circulation but undergo rapid cleavage by lysosomal enzymes upon cellular internalization, leveraging the high protease activity within these compartments <Paper corpusId=\"277415246\" paperTitle=\"(Ianni et al., 2025)\" isShortName></Paper>. This selective release mechanism is essential for controlling the toxicity of the highly potent drugs typically used in ADC construction.\n\nThe interplay between linker parameters - including conjugation chemistry, linker length, and steric hindrance - significantly affects ADC pharmacokinetics, efficacy, and toxicity profiles. Achieving the optimal balance between ADC stability in circulation and efficient payload release at the target site remains a central challenge in linker design <Paper corpusId=\"277415246\" paperTitle=\"(Ianni et al., 2025)\" isShortName></Paper> <Paper corpusId=\"235599751\" paperTitle=\"(Su et al., 2021)\" isShortName></Paper>. This balance is particularly critical for site-specific antibody-drug conjugates, where precise control over drug release kinetics can dramatically influence therapeutic outcomes.\n\nImportantly, the ideal linker chemistry ultimately depends on experimental determination of the optimal combination specific to each ADC. The selection must consider the properties of the target antigen, the characteristics of the payload, and the desired pharmacokinetic profile <Paper corpusId=\"277415246\" paperTitle=\"(Ianni et al., 2025)\" isShortName></Paper> <Paper corpusId=\"14674766\" paperTitle=\"(Jackson et al., 2014)\" isShortName></Paper>. This integrated approach to linker design, considering the entire ADC system rather than the linker in isolation, has proven successful in developing effective therapeutics with improved safety profiles.\n\nThe development of novel dosing strategies, such as dose fractionation approaches, can further optimize the performance of ADCs with different linker designs. These strategies provide valuable guidance for establishing optimal dosing regimens in pre-clinical models and potentially in clinical applications <Paper corpusId=\"235599751\" paperTitle=\"(Su et al., 2021)\" isShortName></Paper>. As understanding of linker-mediated drug release mechanisms continues to advance, so too will the ability to fine-tune ADC performance through strategic linker selection and design.", "citations": [{"id": "(Chis et al., 2022)", "paper": {"corpus_id": 251880235, "title": "Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy", "year": 2022, "venue": "Pharmaceutics", "authors": [{"name": "A. A. Chi\u0219", "authorId": "1931691698"}, {"name": "A. Arseniu", "authorId": "1932174913"}, {"name": "C. Morgovan", "authorId": "27000607"}, {"name": "C. Dobrea", "authorId": "113090506"}, {"name": "Adina Frum", "authorId": "90626113"}, {"name": "A. Juncan", "authorId": "93015110"}, {"name": "Anca Butuca", "authorId": "1436195146"}, {"name": "S. Ghibu", "authorId": "8927176"}, {"name": "F. Gligor", "authorId": "66240760"}, {"name": "L. Rus", "authorId": "27468075"}], "n_citations": 11}, "snippets": ["A key factor, in the design of all these conjugates is the linker which influences the stability of the conjugate, modulates the release of the cytotoxic agent and the pharmacokinetics (Bargh et al., 2019)(Brandl et al., 2020)(Zhong et al., 2021)(Lindberg et al., 2021)(Vhora et al., 2015)."], "score": 0.705078125}, {"id": "(Bargh et al., 2019)", "paper": {"corpus_id": 195879565, "title": "Cleavable linkers in antibody-drug conjugates.", "year": 2019, "venue": "Chemical Society Reviews", "authors": [{"name": "Jonathan D Bargh", "authorId": "150139163"}, {"name": "Albert Isidro-Llobet", "authorId": "1397914841"}, {"name": "J. Parker", "authorId": "16115470"}, {"name": "D. Spring", "authorId": "1761031"}], "n_citations": 290}, "snippets": ["Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clinical treatment of cancer. The properties of the linker between the antibody and the payload are proven to be critical to the success of an ADC. Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clinical development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'. In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biological processes underlying the mechanisms of action of pre-existing technologies. This review summarises the advances in the field of cleavable linker technologies for ADCs."], "score": 0.0}, {"id": "(Zhong et al., 2021)", "paper": {"corpus_id": 232774369, "title": "Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics", "year": 2021, "venue": "Antibodies", "authors": [{"name": "Xiaotian Zhong", "authorId": "38849500"}, {"name": "A. D\u2019Antona", "authorId": "1410913606"}], "n_citations": 30}, "snippets": ["Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago. These biologic drugs are structurally more complex than small molecules, and yet share a similar principle for rational drug discovery and development: That is to start with a pre-defined target and follow with the functional modulation with a therapeutic agent. Despite these tremendous successes, this \"one target one drug\" paradigm has been challenged by complex disease mechanisms that involve multiple pathways and demand new therapeutic routes. A rapidly evolving wave of multispecific biotherapeutics is coming into focus. These new therapeutic drugs are able to engage two or more protein targets via distinct binding interfaces with or without the chemical conjugation to large or small molecules. They possess the potential to not only address disease intricacy but also exploit new therapeutic mechanisms and assess undruggable targets for conventional monospecific biologics. This review focuses on the recent advances in molecular design and applications of major classes of multispecific biotherapeutics drugs, which include immune cells engagers, antibody-drug conjugates, multispecific tetherbodies, biologic matchmakers, and small-scaffold multispecific modalities. Challenges posed by the multispecific biotherapeutics drugs and their future outlooks are also discussed."], "score": 0.0}, {"id": "(Lindberg et al., 2021)", "paper": {"corpus_id": 238745220, "title": "Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy", "year": 2021, "venue": "Molecules", "authors": [{"name": "J. Lindberg", "authorId": "2071115197"}, {"name": "J. Nilvebrant", "authorId": "4559159"}, {"name": "P. Nygren", "authorId": "35284027"}, {"name": "F. Lehmann", "authorId": "49415395"}], "n_citations": 52}, "snippets": ["We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug conjugates used clinically as cancer treatments. While providing both efficacy and favorable tolerability, ADCs have limitations due to their size and complexity. Peptides as tumor-targeting carriers in peptide-drug conjugates (PDCs) offer a number of benefits. Melphalan flufenamide (melflufen) is a highly lipophilic PDC that takes a novel approach by utilizing increased aminopeptidase activity to selectively increase the release and concentration of cytotoxic alkylating agents inside tumor cells. The only other PDC approved currently for clinical use is 177Lu-dotatate, a targeted form of radiotherapy combining a somatostatin analog with a radionuclide. It is approved as a treatment for gastroenteropancreatic neuroendocrine tumors. Results with other PDCs combining synthetic analogs of natural peptide ligands with cytotoxic agents have been mixed. The field of drug conjugates as drug delivery systems for the treatment of cancer continues to advance with the application of new technologies. Melflufen provides a paradigm for rational PDC design, with a targeted mechanism of action and the potential for deepening responses to treatment, maintaining remissions, and eradicating therapy-resistant stem cells."], "score": 0.0}, {"id": "(Buyukgolcigezli et al., 2025)", "paper": {"corpus_id": 276971806, "title": "Opportunities and Challenges in Antibody\u2013Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment", "year": 2025, "venue": "Cancers", "authors": [{"name": "Idil Buyukgolcigezli", "authorId": "2349867663"}, {"name": "Ate\u015f Kutay Tenekeci", "authorId": "2309956062"}, {"name": "\u0130brahim Halil \u015eahin", "authorId": "2259223498"}], "n_citations": 2}, "snippets": ["A subgroup of cleavable linkers contains disulfide bonds that are sensitive to intracellular glutathione, releasing the payload upon the chemical reduction in these bonds by glutathione (Kostova et al., 2021). Such linkers might prove useful for the development of future ADCs for many cancers, including ovarian, head and neck, and lung cancers, since increased tumor glutathione levels have been reported in the literature for these cancers [5,29]", "Site-specific degradation mechanisms of non-cleavable linkers are actively being researched to improve their efficacy over cleavable counterparts [31]."], "score": 0.7041015625}, {"id": "(Kostova et al., 2021)", "paper": {"corpus_id": 235213516, "title": "The Chemistry Behind ADCs", "year": 2021, "venue": "Pharmaceuticals", "authors": [{"name": "V. Kostova", "authorId": "92679096"}, {"name": "P. D\u00e9sos", "authorId": "82823571"}, {"name": "J. Starck", "authorId": "145394555"}, {"name": "A. Kotschy", "authorId": "2118188"}], "n_citations": 70}, "snippets": ["Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of various cancers. Besides a number of approved drugs already on the market, there is a formidable follow-up of ADC candidates in clinical development. While selection of the appropriate antibody (A) and drug payload (D) is dictated by the pharmacology of the targeted disease, one has a broader choice of the conjugating linker (C). In the present paper, we review the chemistry of ADCs with a particular emphasis on the medicinal chemistry perspective, focusing on the chemical methods that enable the efficient assembly of the ADC from its three components and the controlled release of the drug payload."], "score": 0.0}, {"id": "(Ianni et al., 2025)", "paper": {"corpus_id": 277415246, "title": "Unlocking the Complexity of Antibody-Drug Conjugates: A Cutting-Edge LC-HRMS Approach to Refine Drug-to-Antibody Ratio Measurements with Highly Reactive Payloads", "year": 2025, "venue": "International Journal of Molecular Sciences", "authors": [{"name": "Andrea Di Ianni", "authorId": "2219356781"}, {"name": "Kyra J Cowan", "authorId": "2203037437"}, {"name": "Federico Riccardi Sirtori", "authorId": "2220142701"}, {"name": "Luca Barbero", "authorId": "2258323154"}], "n_citations": 0}, "snippets": ["Protease-cleavable linkers are also designed to be stable in plasma, but rapidly release the active drug within lysosomes in cancer cells upon cleavage by lysosomal enzymes [19]. They take advantage of the high levels of protease activity inside lysosomes and include a peptide sequence recognized and cleaved by these proteases. The primary goal of all linkers in ADCs is to ensure the specific release of the active drug within target cells, which is essential for controlling the toxicity of the highly potent drugs used to construct ADCs. However, the balance between efficacy and toxicity changes for the above-mentioned linkers. Moreover, the ideal linker chemistry choice ultimately depends on experimentally determining the optimal combination of the suitable linker, the ideal target antigen, and the desired payload (Jackson et al., 2014)(Su et al., 2021)."], "score": 0.72216796875}, {"id": "(Su et al., 2021)", "paper": {"corpus_id": 235599751, "title": "Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency", "year": 2021, "venue": "Frontiers in Pharmacology", "authors": [{"name": "Dian Su", "authorId": "2065439491"}, {"name": "Donglu Zhang", "authorId": "46335256"}], "n_citations": 69}, "snippets": ["The development of antibody-drug conjugates (ADCs) has significantly been advanced in the past decade given the improvement of payloads, linkers and conjugation methods. In particular, linker design plays a critical role in modulating ADC stability in the systemic circulation and payload release efficiency in the tumors, which thus affects ADC pharmacokinetic (PK), efficacy and toxicity profiles. Previously, we have investigated key linker parameters such as conjugation chemistry (e.g., maleimide vs. disulfide), linker length and linker steric hindrance and their impacts on PK and efficacy profiles. Herein, we discuss our perspectives on development of integrated strategies for linker design to achieve a balance between ADC stability and payload release efficiency for desired efficacy in antigen-expressing xenograft models. The strategies have been successfully applied to the design of site-specific THIOMABTM antibody-drug conjugates (TDCs) with different payloads. We also propose to conduct dose fractionation studies to gain guidance for optimal dosing regimens of ADCs in pre-clinical models."], "score": 0.0}, {"id": "(Jackson et al., 2014)", "paper": {"corpus_id": 14674766, "title": "Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates", "year": 2014, "venue": "Pharmaceutical Research", "authors": [{"name": "D. Jackson", "authorId": "47183270"}, {"name": "D. Stover", "authorId": "6225099"}], "n_citations": 29}, "snippets": ["The treatment options for cancer patients include surgery, chemotherapeutics, radiation therapy, antibody therapy and various combinations of these therapies. The challenge with each therapy is finding the balance between maximizing the anti-tumor efficacy while minimizing the dose limiting toxicities. Antibodies, unlike small molecule chemotherapeutics, selectively bind to cell surface tumor antigens and can be used to deliver radionucleotides or small molecule chemotherapeutic drugs directly to the tumor. Advances in antibody engineering, linker chemistry and the identification of potent cytotoxic drugs led to the recent approval of two antibody drug conjugates to treat breast cancer and lymphoma patients. We will discuss how the observations from the clinical development of antibody drug conjugates can guide the preclinical development of the next generation of antibody drug conjugates."], "score": 0.0}], "table": null}], "cost": 0.540513}}
